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APS       Ammonium persulphate 
ATP       Adenosine triphosphate 
BSA       Bovine Serum Albumin 
cDNA        complementary DNA 
CHO       Chinese Hamster Ovary 
°C       degree Celsius 
dd       double distilled 
DMEM       Dulbecco’s modified Eagle’s medium 
DNA       deoxyribonucleic acid 
dNTP                  deoxy nucleotide triphosphate 
dsDNA                 double stranded DNA 
DTT                  dithiothreitol 
ECL       Enhanced Chemiluminescence 
FCS        Fetal Calf Serum 
Fig       Figure 
g        gram(s) 
h       hour(s) 
HEK        Human Embryonic Kidney 
kDa                   kilo Daltons 
Km       Michaelis- Menten constant 
LB       Luria Bertani broth 
M        Molar       
mM        milli Molar 
µM       micro Molar 
MPP       4-methyl-pyridinium iodide 
PBS                  Phosphate Buffer Saline 
PCR                  Polymerase Chain Reaction 
RNA                   Ribonucleic acid 
rpm        revolutions per minute 
RT-PCR       Reverse Transcriptase PCR 
SEM       Standard error of mean 
SDS                  Sodium dodecyl sulphate 




SDS-PAGE       SDS-Polyacrylamide gel electrophoresis 
TBS        Tris buffered saline 
TEMED                 tetramethylenediamine 
Tris        tris (hydroxymethyl) aminomethane 
UV        Ultraviolet 
V        Volts 
WB        Western Blot 





Chronic Lymphocytic Leukaemia, CLL, is one of the most common forms of leukaemia in the 
elderly. The treatment regimen determines the outcome of patients with CLL and the 
efficiency of this treatment is modulated by the concentration of cancer treating drugs in 
cancer cells. Uptake transporters of the SLC (solute carrier) family can help overcome 
chemoresistance by the application of transporter-specific cytostatics. In the present study, we 
investigated the expression of SLC transporters in six lymphoma cell lines and in CLL patient 
samples. Five of the six cell lines tested, as well as samples from CLL patients demonstrated a 
higher expression of SLC22A1 (OCT1) than in healthy lymphocytes. The uptake of the 
organic cation [3H]MPP into OCT1 stably transfected CHO cells was significantly inhibited 
by irinotecan, mitoxantrone and paclitaxel. The Ki values as determined using Dixon plot 
analyses were 1.71 µM, 85.2 µM and 50.1 µM, respectively. [3H]MPP uptake by OCT2 stably 
transfected CHO cells was inhibited by irinotecan and the Ki value was calculated to be 86.3 
µM. Transporter mediated cytototoxicity of these drugs was analyzed using MTT assays on 
CHO-OCT1, CHO-OCT2, L-428 (B-lymphoma cell line expressing OCT1) and SUDHL-4 
(B-lymphoma cell line with no expression of OCT1). The growth of CHO-OCT1 and CHO-
OCT2 on irinotecan treatment was inhibited by 30% and 23%, respectively, compared to non-
transfected CHO cells. Mitoxantrone resulted in a 45% decrease of CHO-OCT1 cells 
compared to CHO cells, while paclitaxel treatment resulted in a 30% decrease in cell viability 
of CHO-OCT1 cells. In L-428 and SUDHL-4, results were similar with lowered cell viability 
seen in OCT1 expressing L-428 on irinotecan and paclitaxel treatment, by 15% and 45%, 
respectively; with no change in SUDHL-4. The data shown here support the hypothesis that 
sensitivity of cancer cells to cytostatics is mediated by the specific uptake transporter proteins. 
The expression analysis of transporters and the application of transporter-specific cytostatics 











Chronische lymphatische Leukämie (CLL) ist bei älteren Menschen eine der häufigsten 
Formen der Leukämie. Das Behandlungskonzept bestimmt den Krankheitsverlauf der CLL, 
da die Effektivität der Behandlung durch die Konzentration an Krebsmedikamenten in den 
Krebszellen bestimmt wird. Durch die Anwendung transporterspezifischer Zytostatika können 
Aufnahmetransporter der „solute carrier“ (SLC) Familie dazu beitragen, die Chemoresistenz 
von Zellen zu überwinden. In der vorliegenden Arbeit wurde die Expression von SLC 
Transportern in sechs Lymphomzelllinien und in CLL-Patientenmaterial untersucht. Fünf der 
sechs getesteten Zelllinien, sowie die Proben von CLL-Patienten zeigten eine höhere 
Expression des SLC22A1 (OCT1) als gesunde Lymphozyten. Die Aufnahme des organischen 
Kations [3H]MPP in mit OCT1 stabil transfizierte CHO Zellen wurde durch Irinotekan, 
Mitoxantron und Paclitaxel signifikant gehemmt. Mit Hilfe von Dixon Plot Analysen konnten 
Ki-Werte von 1,71 µM, 85,2 µM bzw. 50,1 µM ermittelt werden. Die [
3H]MPP-Aufnahme in 
mit OCT2 stabil transfizierte CHO Zellen wurde durch Irinotekan gehemmt und eine Ki von 
86,3 µM konnte ermittelt werden. Die transportervermittelte Zytotoxizität dieser 
Medikamente wurde unter Verwendung des MTT-Tests an CHO-OCT1, CHO-OCT2; L-428 
(OCT-1 exprimierende B-Lymphomzelllinie) und SUDHL-4 (nicht OCT-1 exprimierende B-
Lymphomzelllinie) getestet. Das Wachstum von CHO-OCT1 und CHO-OCT2 wurde durch 
Irinotekan, verglichen mit nichttransfizierten Zellen, um 30% bzw. 23% reduziert. 
Mitoxantron führte zu einer Abnahme der überlebenden CHO-OCT1 Zellen um 45% 
verglichen mit CHO Zellen, während die Behandlung mit Paclitaxel das Überleben der CHO-
OCT1 Zellen um 30% reduzierte. Versuche mit L-428 und SUDHL-4 führten zu 
vergleichbaren Ergebnissen: Die Behandlung mit Irinotekan und Paclitaxel führte zu einer um 
15% bzw. 45% verminderten Überlebensrate der OCT1 exprimierenden L-428 Zellen, auf das 
Überleben von SUDHL-4 Zellen hatten diese Medikamente keinen Einfluss. Die hier 
gezeigten Daten unterstützen die Hypothese, die Empfindlichkeit von Krebszellen gegenüber 
Zytostatika sei durch spezifische Transportproteine vermittelt. Die Expressionsanalyse von 
Transportern und die Anwendung transporterspezifischer Zytostatika könnten helfen, die 
Krebstherapie auf individuelle Anforderungen maßzuschneidern.  
          
 
 




 1. INTRODUCTION 
1.1 Chronic Lymphocytic Leukaemia 
Leukaemia is a collective term used to describe a group of cancers characterized by an 
abnormal proliferation of leukocytes. Acute leukaemia is due to a rapid increase of 
immature blood cells and immediate treatment is required because of rapid disease 
progression. Chronic leukaemia is characterized by a slow buildup of mature, albeit 
abnormal, blood cells. It can take months or years to progress and unlike acute 
leukaemia, treatment of chronic leukaemia involves monitoring the disease to ensure 
maximum efficacy. Depending on the blood cell affected, leukaemia may further be 
divided into myeloid or lymphocytic. In myeloid leukaemia, mutations develop in the 
marrow cell which goes on to form red blood cells and platelets. Lymphocytic 
leukaemia starts with a cancerous change in the marrow cell that develops into 
lymphocytes (128). 
Acute myeloid leukaemia (AML) is morphologically defined by abnormal 
promyelocytes (76). The disease is characterized by frequent coagulopathy associated 
with bleeding. The disease incidence increases with age and it accounts for 90% of all 
acute leukaemias in adults.  
Chronic myeloid leukaemia, CML, is characterized by the presence of the Philadelphia 
(Ph) chromosome, formed due to translocation between two chromosomes. 
Translocation between the long arms of chromosomes 9 and 22 results in the 
formation of two new genes: BCR-ABL and ABL-BCR. The BCR-AML gene 
encodes a protein with deregulated tyrosine kinase activity, crucial for malignant 
transformation in CML (39). 
Acute lymphoblastic leukaemia, ALL, results in the accumulation of early B- and T-
lymphocyte progenitors in the bone marrow. ALL affects children and adults, with 
highest incidence in children between the ages of 2-5 (30). 
B-cell chronic lymphocytic leukaemia (B-CLL) is characterized by the accumulation 
of abnormal lymphocytes in the blood and the bone marrow. One of the most common 
forms of leukaemia in North America and Europe, it mainly affects the elderly (29).  




CLL is a lymphoproliferative disease and the B-CLL cells are CD5+, CD19+, CD20+ 
and CD23+, mature, non-functional B-cells (19). B-CLL cells can account for up to 
99% of circulating peripheral blood mononuclear cells and compared to normal B-
cells, B-CLL cells can survive for a few months in the blood circulation. This increase 
in abnormal B-CLL cells, combined with a decrease in normal immune cells, results in 
immune deficiency in CLL (47).  
Two classification systems are commonly used to divide patient populations into three 
prognostic groups: Rai system (Table 1.1), which is commonly used in USA; and the 
Binet classification system (Table 1.2), more popular in Europe (9). These systems 
provide the basis of treatment and medical follow-up.  
Table 1.1 Rai classification system  
Risk level Stage Clinical features at diagnosis Median survival 
time (years) 
Low 0 Blood and marrow lymphocytosis ≥10 
Intermediate I Lymphocytosis and lymphadenopathy 9 
II Lymphocytosis and splenomegaly 5 
High III Lymphocytosis and anaemia 5 
IV Lymphocytosis and thrombocytopenia 5 
 
Table 1.2 Binet classification system 
Stage Clinical features at diagnosis Median survival 
time (years) 
A Blood and marrow lymphocytosis and less than three 
areas of palpable lymphoid involvement 
> 7-10 
B Same with three or more areas of palpable lymphoid 
involvement 
5-7 
C Same plus anaemia or thrombocytopenia < 2-5 
 
Characterized by a loss of proper apoptotic controls, B-CLL may be influenced by 
either activation of anti-apoptosis pathways or blockage of pro-apoptosis pathways 




(22). Many gene and chromosomal abnormalities as well as advancing age correlate 
with CLL disease development. Several chromosomal abnormalities occur in CLL 
(31). The most common includes the loss of a region of chromosome 13 encoding 
microRNAs, which may play a role in silencing certain target genes (5). Deletion of 
miR-15a and miR-16-1 are seen in more than 50% CLL cases (80) and is also 
associated with an increase in Bcl2, an inhibitor of apoptosis (9). The deletion of miR-
15a and miR-16-1 is associated with good prognosis. Trisomy 12 occurs in 15% cases 
but has no significant prognostic influence (9). The tumour suppressor and pro-
apoptotic gene, p53, is also often deleted as a consequence of deletion on chromosome 
17 and this is associated with a bad median survival time (109;127). The loss of p53 is 
associated with chemotherapeutic resistance to alkylating agents like chlorambucil and 
purine analogues like fludarabine (9). 
Protein abnormalities are common, as represented by ZAP-70. Expressed in T-
lymphocytes, natural killer cells and activated splenic B-cells, ZAP-70 is a receptor-
associated protein tyrosine kinase (3). ZAP-70 can promote the survival of B-CLL 
cells by enhanced B-cell receptor signaling and ZAP-70 expression in B-cells is 
frequently used as a prognostic marker for CLL (2).  Another prognostic marker for 
CLL patients is the mutational status of the immunoglobulin heavy chain (IgVH). 
Patients with somatic unmutated IgVH develop progressive CLL with poorer prognosis 
than those with mutated IgVH. B cells from patients with favourable prognostic 
markers of CLL- mutated IgVH, CD38
-, ZAP-70-, are less capable of triggering 
apoptosis, survival or proliferation. This lack of receptor stimulation could be due to 
the inability to bind antigen by B- cell receptors, and favours a less aggressive form of 
CLL (25). Figure 1.1 below depicts the development and evolution of CLL cells 
resulting in mutated or unmutated CLL. 





Fig 1.1  Model depicting the development and evolution of CLL cells. An initial inducing 
lesion occurs in a single B lymphocyte (pink cell in upper and lower portions of Panel A). 
Interactions between antigens and B-cell receptors of adequate affinity induce clonal 
amplification (Panel B). The initial inducing lesion provides the marked cell with a growth 
advantage over other clones stimulated by the same or other antigens. In clones destined to 
become unmutated CLL cells, repetitive interactions between antigens and polyreactive B-cell 
receptors of the initially selected clone promote clonal growth, which persists because V-gene 
mutations do not occur (Panel C, top). In others, destined to become mutated CLL cells (Panel 
C, bottom), V-gene mutations develop that can abrogate the polyreactivity of the B-cell 
receptors and thereby alter their ability to bind the original antigen or autoantigen (“clonal 
ignorance”). Alternatively, these mutated cells become anergic owing to excessive B-cell–
receptor stimulation because of the acquisition of more avid receptors. In both instances, the 
promoting effect of antigenic stimulation is neutralized. Additional DNA mutations cause the 
cells to become leukaemic (Panel D). Continued cycling leads to other genetic changes (e.g., 
deletions at 13q, 11q, and 17p or duplication of chromosome 12) that determine the course of 
the disease (Panel E) (Figure reproduced without permission from Chiorazzi et al, 2005).  
Chronic lymphocytic leukaemia may be stable or progressive. Patients suffering from 
stable CLL can survive long periods without treatment while progressive CLL is 
characterized by the rapid doubling-time of B-CLL cells, and can thus be fatal in a 
short time (22). Chemotherapy for CLL involves administration of drugs like 
fludarabine (70) or cyclophosphamide. Fludarabine is a purine analog and can induce 




p53- dependent apoptosis. Monoclonal antibodies for CLL treatment have also been 
developed and include anti-CD52 (Alemtuzumab) and anti-CD20 (Rituximab) (2). 
Bendamustine, which has properties of an alkylating agent as well as antimetabolites, 
is also gaining use in the treatment of this disease (7;94).  
The outcome of patients with leukaemia is affected by the treatment regimen. The 
efficacy of cytostatic drugs in cancer therapy is modulated by the concentration of 
these drugs in cancer cells (54). Uptake transporters belonging to the superfamily of 
solute carriers (SLC) and efflux pumps belonging to the ATP-binding cassette 
transporter (ABC transporter) superfamily are the key agents controlling drug 
concentrations in cells. The efflux ABC transporters are one of the key factors 
responsible for the chemoresistance of tumours, due to their high expression in these 
cells (11;12). Solute carrier transporters, SLCs, are represented by 47 families. 
Broadly expressed in the human body, SLCs may obtain energy for substance (drug) 
translocation from the electrochemical gradient of Na+, H+ and organic ions such as 
dicarboxylates (100). 
1.2 Transport systems 
Membrane transporters mediate the absorption, distribution and excretion of most 
nutrients, xenobiotics, drugs, environmental toxins and their metabolites. By 
controlling the cellular milieu through the influx and efflux of nutrients, metabolites 
and drugs, transporter proteins play essential roles in cell function, proliferation and 
death (54).  
1.2.1 Efflux transporters 
ATP-binding cassette (ABC) transporters are primary-active transporters that utilize 
ATP hydrolysis as the energy source to drive active transport. 50 different ABC 
transporter genes have been identified and these are grouped into seven families based 
on sequence homology (54;96). These ATP-dependent transporters mediate the 
translocation of various substrates across membranes. ABC transporters consist of at 
least four domains: two transmembrane units consisting of six transmembrane 
domains each, embedded in the membrane bilayer; and two ABCs binding domains, 
located in the cytoplasm (96).   




ABC transporters may function as either importers or exporters, transporting substrate 
molecules in or out of cells. ABC transporters that function as importers are only 
reported in prokaryotes. In eukaryotes, ABC transporters are important in the cellular 
exit of lipids, fatty acids and cholesterol (96).  
A variety of ABC transporters have been implicated in chemoresistance of cancer cells 
by mediating the efflux of chemotherapeutic drugs (115). Various factors may result in 
the increased expression of ABC efflux transporters in drug-resistant cancer cells. 
These include altered activity of transcriptional factors, gene polymorphisms as well 
as changes in the methylation status of promoters (60). These factors modulating the 
functional characteristics of transporters are directly responsible for drug 
pharmacokinetics.  
The overexpression of MDR1 (ABCB1; P-glycoprotein) in cancer cells confers 
chemoresistance to various classes of compounds with unrelated chemical structures. 
Known substrates of MDR1 include etoposide and vinblastine (95). Polymorphisms in 
the gene encoding MDR1 can significantly affect response to pharmacotherapy for 
many diseases (54). Recently, MDR1 gene polymorphisms have been associated with 
MDR1 activity in B-CLL (57). According to Jamroziak and colleagues, a single 
nucleotide polymorphism in MDR1, C3435T, increases the risk of developing B-CLL, 
possibly due to decreased protection against MDR1 substrate carcinogens.  
MRP1, Multidrug Resistance Protein 1 (ABCC1), has been shown to transport 
glutathione and other drug conjugates. Coupling to glutathione also appears to play a 
role in the transport of MRP1 substrates. Since glutathione is a physiological substrate 
of MRP1, this transporter has been suggested to play a role in the cellular 
antioxidative defense system (71-73). 
 Overexpression of MRP2, Multidrug Resistance Protein 2 (ABCC2), can induce 
resistance against various drugs like cisplatin, doxorubicin and methotrexate. Genetic 
variations in MRP2 can lead to nephrotoxicity due to reduced drug clearance (55).  
The ABC transporters are relatively well characterized, with many studies on their 
substrate specificity and mechanism of substrate efflux. In the current study, we were 
interested in the influx of cytostatics into tumour cells; and therefore we concentrated 
on the expression and functional characterization of SLC transporters. 




1.2.2 Influx transporters 
The solute carrier (SLC) superfamily is a major group of membrane transporters 
responsible for the uptake of nutrients, metabolites, drugs and toxins. At present there 
are 47 known SLC families and these are organized on the basis of alignment 
similarities and substrate specificities (49). SLC transporters undergo sequential 
conformational changes during the transport cycle and these proteins are capable of 
transporting more than one substrate simultaneously (6). The specific SLC transporter 
families studied in the course of this work are briefly described. 
1.2.2.1  SLC7  
SLC7 family of transporters includes two system L transporters which function 
independently of Na+ and other ions to transport large, neutral amino acids across 
plasma membranes (Table 1.3). They function as obligatory exchangers with a 1:1 
stoichiometry and the activity of LAT1 and LAT2 depends on the amount of 
intracellular substrate amino acids (59). The single membrane spanning glycoprotein 
4F2 heavy chain (hc) is essential for amino acid transport by LATs (59). These 
transporters consist of membrane spanning light chain and heavy chain. An important 
cytostatic, melphalan, is a known substrate of LAT1 (66). 
Table 1.3 Tissue distribution and substrates of selected members of SLC7 family 
Gene  Protein  Tissue distribution Substrates/ cytostatics  
SLC7A5 LAT1 Brain, placenta, 
testis, tumour cells, 
bone marrow 
 
L-type amino acids, L-Dopa, 
Melphalan 
SLC7A8 LAT2 Brain, placenta, 
testis, kidney, small 
intestine 
 








1.2.2.2  SLC10  
The sodium bile salt co-transporter family includes the NTCP and ASBT transporters. 
Both systems mediate sodium-dependent uptake of conjugated and unconjugated bile 
salts (Table 1.4). The driving force for the uptake is provided by the inwardly directed 
Na+ gradient maintained by the basolateral Na+, K+-ATPase as well as the negative 
intracellular potential (37). The two C-terminal putative transmembrane domains are 
hypothesized to constitute an important part of the binding pocket for bile salts in 
these transporters. SLC10 transporters can serve as possible targets of drugs 
conjugated to bile salts. The uptake of modified chlorambucil which keeps its potency 
even after conjugation to bile salts has been shown for NTCP (67).  
Table 1.4 Tissue distribution and substrates of selected members of SLC10 family 
Gene  Protein  Tissue distribution Substrates/ cytostatics  




SLC10A2 ASBT Biliary tract, ileum, kidney 
 
Bile salts  
 
 
1.2.2.3  SLC13 
The SLC13 gene family consists of sodium-coupled transporters mediating the 
transport of anions (like sulphate) and dicarboxylates. The five members of this family 
are electrogenic transporters, producing an inward current in the presence of sodium 
and substrates. Consisting of 11 transmembrane domains, the carboxy terminal half of 
these proteins is most important for determining function while the TMDs 9 and 10 
form part of the substrate permeation pathway. All members contain one or two N-
glycosylation sites at the C-terminus. NaDC3 is encoded by SLC13A3 gene and is a 
high affinity Na+/ dicarboxylate transporter (Table 1.5). Transport by NaDC3 involves 
three Na+ ions with each substrate and is inhibited by millimolar concentrations of 
lithium (88). 
 




Table 1.5 Tissue distribution and substrates of NaDC3 from SLC13 family 










1.2.2.4  SLC16  
The monocarboxylate co-transporter (MCT) family comprises 14 members. MCT1-4 
are known to catalyze the proton-linked transport of metabolically important 
monocarboxylates like lactate, pyruvate and ketone bodies (Table 1.6). Lactic acid 
transport by the MCTs across the plasma membrane is essential for the metabolism 
and the pH regulation of cells. The different MCT isoforms remove the lactic acid 
produced by glycolysis and allow uptake of lactate by cells utilizing it for 
gluconeogenesis (liver and kidney cells) or as a respiratory fuel (heart and red muscle 
cells). 10-12 α-helical transmembrane domains are predicted for MCTs, with the N- 
and C-termini located within the cytoplasm. C-terminus and the large intracellular 
loop between TMD 6 and 7 offers sites for large sequence variations between different 
isoforms (45).  
Table 1.6 Tissue distribution and substrates of selected members of SLC16 family 
Gene  Protein  Tissue distribution Substrates/ cytostatics  
SLC16A1 MCT1 Ubiquitous  Lactate, pyruvate, ketone 
bodies 
SLC16A3 MCT4 Chondrocytes, heart, lung, 
placenta, skeletal muscle, 
testis  
Lactate, pyruvate, ketone 
bodies  
SLC16A7 MCT2 Brain, kidney  Pyruvate, lactate, ketone 
bodies  
 
1.2.2.5  SLC19 
The SLC19 gene family plays an important role in the transport and homeostasis of 
folate and thiamine in the body. The three members are expressed ubiquitously. 




SLC19A1 (RFT) mediates transport of folate and its derivatives existing as anions at 
physiological pH, while SLC19A2 (ThTr1) and SLC19A3 (ThTr2) transport thiamine, 
which exists as a cation at physiological pH (Table 1.7). Folate influx via RFT is 
stimulated by an inwardly directed H+ gradient (pHout<pHin), suggesting folate/H
+ 
symport or folate/OH- antiport. Thiamine influx via ThTr1 and ThTr2 is enhanced by 
an outwardly directed H+ gradient (pHout>pHin), suggesting thiamine/H
+ antiport. All 
three proteins are composed of 12 transmembrane domains with N-glycosylation sites 
(35). 
Table 1.7 Tissue distribution and substrates of selected members of SLC19 family 
Gene  Protein  Tissue distribution Substrates/ cytostatics  
SLC19A1 RFT Ubiquitous  Folate, Methotrexate  
SLC19A2 ThTr1 Ubiquitous Thiamine 
SLC19A3 ThTr2 Ubiquitous Thiamine 
 
1.2.2.6  SLCO (SLC21) 
SLCO family members are organic anion transporting polypeptides (OATPs). They 
share a predicted membrane topology of 12 transmembrane domains with a large 5th 
extracellular loop. The OATPs contain N-glycosylation sites in the extracellular loops 
2, 3 and 5, and in the transmembrane domain 6 (44). OATPs have a wide tissue 
distribution and mediate the cellular uptake of a broad range of compounds, including 
hormones, bile salts, steroids, antivirals and cytostatics (Table 1.8).  
Table 1.8 Tissue distribution and substrates of selected members of SLC21 family 
Gene  Protein  Tissue distribution Substrates/ cytostatics  
OATP1A2 OATP-A Brain, testis Prostaglandin E2, Ouabain, 
Chlorambuciltaurocholate  
OATP1B1 OATP-C Hepatocytes  Bilirubin, Leukotrienes, 
Thyroxine, Methotrexate, 
Taurocholate  
OATP2B1 OATP-B Ubiquitous  Prostaglandin E2, 
Benzylpenicillin  




OATP3A1 OATP-D Non-pigmented human 
ciliary body epithelium  
Prostaglandin E2, 
Benzylpenicillin  
OATP4A1 OATP-E Ubiquitous  Prostaglandin E2, 
Taurocholate, Thyroxine  
 
1.2.2.7  SLC22 
Most transporters of the SLC22 gene family are polyspecific, being able to transport 
different substrates. The transporters have a predicted membrane topology of 12 α-
helical transmembrane domains, a large glycosylated loop between TMDs 1 and 2, 
and a large intracellular loop between TMDs 6 and 7 with sites for phosphorylation. 
The SLC22 family includes organic cation transporters as well as organic anion 
transporters. Organic Cation Transporters, the OCTs, mediate the uptake of organic 
cations, but some weak bases, non-charged, as well as some anionic compounds are 
also transported (8;62;63). Organic anion transporters, the OATs, operate as anion 
exchangers. With a broad specificity, the OATs are known to interact with many 
commonly used anionic drugs like antibiotics and antivirals (100). Since the SLC22 
family transporters are typically found at boundary epithelia, these play an important 
role in distribution of drugs (Table 1.9).  
Table1.9 Tissue distribution and substrates of selected members of SLC22 family 
Gene  Protein  Tissue distribution Substrates/ cytostatics  
SLC22A1 OCT1 Liver  TEA, MPP,  serotonin, 
prostaglandin E2 
SLC22A2 OCT2 Kidney, brain, neurons  TEA, MPP, choline, 
dopamine, histamine, 
norepinephrine, cisplatin  
SLC22A3 OCT3 Liver, skeletal muscle, 
placenta, kidney, heart, 
lung, brain  
TEA, MPP, guanidine, 
dopamine, norepinephrine, 
histamine  
SLC22A6 OAT1 Kidney, brain  PAH, prostaglandins,  
methotrexate, cisplatin  
SLC22A7 OAT2 Liver, kidney  PAH, dicarboxylates, PGE2, 
salicylate, methotrexate, 5-
fluorouracil  




SLC22A8 OAT3 Kidney, brain, skeletal 
muscle developing bone  
PAH, estrone sulphate, 
methotrexate  
SLC22A11 OAT4 Kidney, placenta Estrone sulphate, 
ochratoxin A, prostaglandin 
E2, prostaglandin F2α, 
methotrexate  
SLC22A16 OCT6 Testis, bone marrow, 




1.2.2.8  SLC28 
The SLC28 family, at present, includes three concentrative nucleoside transporters: 
CNT1 (SLC28A1), CNT2 (SLC28A2) and CNT3 (SLC28A3). These proteins are 
membrane bound transporters and mediate a high affinity transport of nucleosides and 
nucleoside analogs actively into cells by coupling transport to the inwardly directed 
sodium gradient (41). The SLC28 family transporters consist of 13 transmembrane 
domains with the cation and substrate recognition sites in the carboxy half of the 
protein. These transporters are located in the plasma membrane of many cell types and 
are involved in the tissue-specific uptake of antiviral and anticancer nucleoside 
analogs. The following table (Table 1.10) gives the tissue distribution and known 
substrates of SLC28 transporters. 
Table 1.10 Tissue distribution and substrates of selected members of SLC28 
family 
Gene Protein  Tissue distribution Substrates/ cytostatics  
SLC28A1 CNT1 Kidney, liver, small intestine Pyrimidine nucleosides, 
adenosine, gemcitabine 
SLC28A2 CNT2 Brain, colon, heart, kidney, 
liver, pancreas, placenta, 




SLC28A3 CNT3 Bone marrow, intestine, liver, 
lung, mammary glands, 
pancreas, placenta, prostrate, 
testis, trachea 









1.2.2.9  SLC29 
Equilibrative nucleoside transporters, ENTs, belong to the human SLC29 family of 
proteins. The four members of this family have a predicted topology of 11 
transmembrane domains with a cytoplasmic N-terminus and an extracellular C-
terminus. The four isoforms are widely distributed in mammalian tissues and play a 
role in transepithelial nucleoside transport (4). The ENTs are also responsible for the 
cellular uptake of nucleoside analogs used in cancer therapy (1) (Table 1.11).  
Table 1.11 Tissue distribution and substrates of selected members of SLC29 
family 
Gene Protein  Tissue distribution Substrates/ cytostatics  
SLC29A1 ENT1 Ubiquitous Purine and pyrimidine 
nucleosides, gemcitabine, 
cladrabine, fludarabine, 
SLC29A2 ENT2 Ubiquitous Purine and pyrimidine 
nucleosides and nucleobases, 
gemcitabine, cladrabine, 
fludarabine, 
SLC29A3 ENT3 Ubiquitous Purine and pyrimidine 
nucleosides 
 
1.3 Antitumour drugs 
Cytostatic drugs have the ability to prevent growth and proliferation of cells. They are 
often used to prevent growth and development of malignant cells and neoplasms; and 
they are therefore referred to as anti-neoplastic drugs.  Anti-cancer drugs can be 
broadly classified into three: (i) those acting on DNA, (ii) drugs acting on mitotic 
spindle; and (iii) drugs acting on steroid hormone receptors. 


















 Fig 1.2 Classification of anticancer drugs on the basis of target of drug action 
 
1.3.1 Cytostatics acting on DNA 
1.3.1.1 Alkylating drugs 
Drugs acting on DNA include covalent DNA binding drugs, the alkylating agents. 
Alkylating cytostatics function by forming covalent bonds with DNA, RNA or 
proteins resulting in adducts with an added methyl or ethyl group. Highly reactive, 
alkylating drugs substitute an alkyl group for the hydrogen atoms in cellular 
molecules, causing single or double strand breaks in DNA, thus preventing replication 
of the DNA. They are cell cycle non-specific and form the largest class of anticancer 
drugs. Examples include chlorambucil and cyclophosphamide. 
Table 1.12 Alkylating drugs used in this work, their use in therapy and 
transporters involved in their uptake into cells 
Name Disease treated Transporter involved in 
uptake 








Melphalan Multiple myeloma, ovarian 
cancer (116) 
LAT1, OCT3 (107) 




Cyclophosphamide Breast cancer, leukaemia, 
ovarian cancer (21;116) 
Not identified 
Ifosfamide Testicular cancer, acute 
lymphocytic leukaemia, 
breast cancer, bone cancer 
(34)   
MCT1 (20)  
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  Fig 1.3 Structures of alkylating drugs used in this study  
1.3.1.2  Free radical forming drugs 
Non covalent binding drugs include intercalating drugs. These have planar regions that 
stack between paired bases in DNA forming drug-DNA interaction. Free radical 
damage causes DNA strand breaks. Examples include anthracyclines like doxorubicin 
and daunorubicin.  




1.3.1.3  Antimetabolites 
Antimetabolites generally alter the synthesis of RNA or DNA. Structural analogues of 
nucleotides are incorporated into cell components as if they were essential pyrimidine 
or purine and disrupt the synthesis of nucleic acids. 5-Fluorouracil is a pyrimidine 
analog while 6-Mercaptopurine is a purine analog. Other antimetabolites disrupt 
essential enzymatic processes of metabolism, like methotrexate. Sugar analogs like 
cytosine arabinoside are also used.  
Table 1.13 Antimetabolites used in this work, their use in therapy and 
transporters involved in their uptake into cells 
Name Disease treated Transporter involved in 
uptake 
Fludarabine Blood cancer (47) ENT1, ENT2, CNT2, 
CNT3 (77;82;83;91) 
Gemcitabine Lung, pancreatic, bladder 
cancer (38) 
ENT1, ENT2 (38) 
Methotrexate Acute lymphoblastic 
leukaemia, Crohn’s disease, 
psoriasis (92) 








Cladribine Blood cancer (101) ENT1, ENT2, CNT2, 
CNT3 (91) 
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   Fig 1.4 Structures of antimetabolites used in this study 
1.3.1.4  Topoisomerase inhibitors 
DNA topoisomerase inhibitors block DNA synthesis by inhibiting the re-ligation of 
DNA double strands. Examples are etoposide and mitoxantrone which stabilize the 
topoisomerase II- DNA complex, preventing it from making a topological change, 
resulting in irreversible double strand break. 
Irinotecan is an example of topoisomerase I inhibitor which is activated to its 
metabolite SN-38 by hydrolysis.  The inhibition of topoisomerase I by the active 
metabolite SN-38 eventually leads to inhibition of both DNA replication and 
transcription. 
Table 1.14 Topoisomerase inhibitors used in this work, their use in therapy and 
transporters involved in their uptake into cells 
Name Disease treated Transporter involved in 
uptake 




Etoposide Lung, testicular cancer, 
lymphoma, non-lymphocytic 
Not identified 
































                     Mitoxantrone    Etoposide 












                                                            Irinotecan 
  Fig 1.5 Structures of topoisomerase inhibitors used in this study 
1.3.2 Cytostatics acting on mitotic spindle 
Inhibitors of chromatin function include microtubule inhibitors like vincristine, 
vinblastine and paclitaxel. These bind to tubulin, inhibiting microtubule and mitotic 
spindle formation. Cells are arrested in metaphase and cell division stopped.  
Table 1.15 Drugs acting on the mitotic spindle used in this work, their use in 
therapy and transporters involved in their uptake into cells 
Name Disease treated Transporter involved in 
uptake 
Vincristine Non-Hodgkin’s lymphoma, 








Vinblastine Hodgkin’s lymphoma, non-
small cell lung cancer, breast 
cancer, testicular cancer, 
urothelial cancer (110) 
Not identified 
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 Fig 1.6 Structures of drugs acting on the mitotic spindle used in this study 
 
1.3.3 Cytostatics acting on steroid hormone receptors 
Drugs affecting endocrine function include glucocorticoids like prednisone. The 
application of these drugs manipulates the hormone environment of hormone- 
responsive tumours. An example is tamoxifen which is used as a synthetic anti-
estrogen in breast cancer treatment. It competes with estrogen at the receptors. 
Tamoxifen binding results in the inhibition of estrogen response and death of 
malignant cells dependent on estrogen for survival. 




Table 1.16 Drugs acting on steroid hormone receptors used in this work, their use 
in therapy and transporters involved in their uptake into cells 
Name Disease treated Transporter involved in 
uptake 






Clodronic acid Paget's disease, malignant 
tumoral hypercalcemia,  
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The effective treatment of CLL using various cytostatics can be modulated by active 
transport of these drugs in cancer cells. Uptake transporters interact with specific 
drugs and are capable of transporting these substrates into cells. The use of cytostatics 
specific for uptake transporters present in cancer cells can increase the concentration 
of these drugs in tumour cells. Chemoresistance, effected in part by the action of 




            Chemoresistant            Chemosensitive 
Fig 1.8  Chemoresistance may be overcome by targeting SLC transporters for drug 
uptake 
The aims of this study were threefold: we examined the expression of SLC 
transporters in lymphoma cell lines and in patients of CLL. Secondly, the interaction 
of various cytostatics with transporters was determined. Lastly, we investigated the 
transporter-mediated cytotoxicity of selected drugs in cell lines expressing specific 
transporters and also in tumour cells.  
In an additional project, we generated stably transfected NaDC3 cell line. This cell 
line will be used for elucidating NaDC3-cytostatics’ interactions.  





2.1 Cell lines 
Cell Line        Provider  
Flp-In T-Rex HEK 293      Invitrogen 
CHO-OCT1, CHO-OCT2, CHO-K1     Prof. Koepsell, Wuerzburg 
All lymphoma cell lines were provided by Prof Wulf, Dept of Haematology and Oncology. 
B-lymphoma cell lines: 
Karpas-422  
Organism    Homo sapiens (Human female, 73 years old) 
Disease    Lymphoma, follicular, B cell 
Raji 
Organism    Homo sapiens (Human male, 12 years old) 
Disease    Burkitt’s lymphoma 
SUDHL-4 
Organism    Homo sapiens 
Disease    non-Hodkin’s lymphoma 
L-428 
Organism    Homo sapiens (Human female, 37 years old) 
Disease    Hodkin’s lymphoma  
T-lymphoma cell lines:  
Jurkat 
Organism    Homo sapiens (Human male, 14 years old) 
Disease    Acute lymphoblastic leukaemia 





Organism    Homo sapiens  
Disease    T cell lymphoma 
2.2 Oligonucleotide primers 
Sequence specific primers for RT-PCR were obtained from MWG Biotech AG (Matrinsried, 
Germany) and are listed in Tables 2.1-2.10 below.  
Table 2.1 Primers used for the PCR screening of GAPDH. 




GAPDH GAPDH_334 for TCACCATCTTCCAGGAGCG  
582 
 
58.0 GAPDH_905 rev CTGCTTCACCACCTTCTTGA 
Table 2.2 Primers used for the PCR screening of SLC7 family transporters. 






LAT1_1082 for CAATGGGTCCCTGTTCACAT  
144 
 




LAT2_1048 for CTTCGGAGGACTGGCTGGGT  
180 
 
59.5 LAT2_1227 rev GTGAGGAGCAATAAGCAGATGG
CA 
Table 2.3 Primers used for the PCR screening of SLC10 family transporters. 






NTCP_332 for CGGCTGAAGAACATTGAGGCAC  
144 
 
58.5 NTCP_475 rev AAGGGCACAGAAGGTGGAGC 
SLC10A2 
(ASBT) 
ASBT_1019 for ATGCCGCTGTGCCTCCTTATC  
104 
 








Table 2.4 Primers used for the PCR screening of SLC13 family transporters. 







NaDC3_1607 for ACTCCATCGCCTTCGCCTCT  
116 
 
59.0 NaDC3_1723 rev CTGTGCCCAGGTATTCATAGCCA
A 
Table 2.5 Primers used for the PCR screening of SLC16 family transporters. 






MCT1_1383 for TGGAATGCTGTCCTGTCCTC  
182 
 
54.5 MCT1_1564 rev CTCCTTCTGTGTCTTTCTGGTCCG 
SLC16A7 
(MCT2) 
MCT2_586 for CCTCACTATGGGATTCATTACAGG  
235 
 
54.5 MCT2_843 rev AGCCACACAGGCATTCAAA 
SLC16A3 
(MCT4) 
MCT4_1132 for AGCCACACAGGCATTCAAA  
180 
 
58.0 MCT4_1311 rev GCTCTTTGGGCTTCTTCCTAATGC 
Table 2.6 Primers used for the PCR screening of SLC19 family transporters. 






RTF_1156 for TCTGGCTGTGCTATGCGGC  
153 
 
59.0 RTF_1308 rev TGGTCTTGACGATGGTGGCAAAG 
SLC19A2 
(ThTr1) 
ThTr_1246 for GGGTAACATTTGGGTGTGC  
174 
 
53.0 ThTr_1418 rev ATTAGAGTGAGCAGCGTCTG 
Table 2.7 Primers used for the PCR screening of SLCO family transporters. 

























































OATP-E_1065 rev GCGGTGAAGAAAGCAGCGG 
Table 2.8 Primers used for the PCR screening of SLC22 family transporters.  






OCT1_133 for GCTATGAAGTGGACTGGAACC  
216 
 
54.5 OCT1_481 rev CAAACAAGAAGCCCGCATTC 
SLC22A2 
(OCT2) 
OCT2_2695 for AGTCTGCCTGGTCAATGCT  
105 
 
54.5 OCT2_2798 rev AGGAATGGCGTGATGATGC 
SLC22A3 
(OCT3) 
OCT3_1336 for ACAGTGGCTACATTGGGAAGA  
113 
 
54.5 OCT3_1448 rev GAACAGAGCGAAACTCCGAA 
SLC22A6 
(OAT1) 
OAT1_956 for GGGCACCTTGATTGGCTATGTCTA  
243 
 
58.5 OAT1_1155 rev TTGGCTCCTTCTTCCCGCTTC 
SLC22A7 
(OAT2) 
OAT2_841 for CGCTGGCTTCTGACCCAAGG  
222 
 
59.5 OAT2_1062 rev TCCGAACCACACCACCACG 
SLC22A8 
(OAT3) 
OAT3_1223 for GTCCCAGCCAAGTTCATCACCA  
146 
 
59.5 OAT3_1368 rev GCCAATACTGTCCTCACGGTCTG 
SLC22A1
1 (OAT4) 
OAT4_510 for TCCTGGTGGGCTCCTTTAT  
134 
 
60.1 OAT4_623 rev GCAGTAGATGACGAATGTTGG 
 
 




Table 2.9 Primers used for the PCR screening of SLC28 family transporters. 












CNT1_1317 rev AAAGTCCAGCACAGCCAGGAAC 
SLC28A2 
(CNT2) 
CNT2_1173 for TGTGCTCTCGCCTCATCAAAGC  
103 
 
58.5 CNT2_1254 rev GGACATTCCTCTCCTTCCCACG 
SLC28A3 
(CNT3) 
CNT3_267 for AGTTGAGCAGGATTCTCCAAG  
144 
 
54.0 CNT3_409 rev CAGATGATGTGCCGAAGAGT 
Table 2.10 Primers used for the PCR screening of SLC29 family transporters. 






ENT1_1348 for CGAGCACGATGCCTGGTTCA  
105 
 
58.5 ENT1_1433 rev GCTGGCTTCACTTTCTTGGGC 
SLC29A2 
(ENT2) 
ENT2_807 for GGAATCAGAGCCAGATGAGCCC  
123 
 
59.0 ENT2_930 rev GGGAAGACGGACAGGGTGACT 
SLC29A3 
(ENT3) 
ENT3_601 for TGAGGAACTCCCAGGCACTGAT  
146 
 
59.0 ENT3_746 rev GAGCACGAGGAAGATGGTGGC 
 
2.3 Antibodies 
Antibody   Stock concentration  Provider/ Catalogue Number 
p53 (DO-1)   200µg/ml    Santa Cruz Biotechnology/ 
mouse monoclonal IgG2a       sc126 
actin    100µg/ml    Dianova/ DLN-07274               
mouse monoclonal IgG1 
Goat anti-mouse IgG  1.0mg/ml    Calbiochem/ 401215 
 




2.4 Plasmid vectors 
Vector       Provider/ Catalogue Number 
pcDNA5/FRT/TO       Invitrogen/ V6520-20  
pDONR221        Invitrogen/ 12536-017 
pEF5/FRT/V5-DEST       Invitrogen/ V6020-20  
pOG44        Invitrogen/ V6005-20 
2.5 Kits 
Kit name       Provider/ Catalogue Number 
BP Clonase II Enzyme Mix      Invitrogen/ 11789-020 
LR Clonase II Enzyme Mix      Invitrogen/ 11791-019 
Gateway Vector Conversion System     Invitrogen/ 11828-029      
with One Shot ccdB Survival Competent Cells 
CompactPrep Plasmid Mini Core Kit    Qiagen/ 12745 
Nucleospin Plasmid       Macherey Nagel/  
         40588.50 
M-MuLV Reverse Transcriptase, RNase H minus   AppliChem/ A5211,50000 
2.6 Cloning competent cells 
Bacteria strains used for maintenance of plasmid constructs are listed below.  
Cells    Provider/ Catalogue number  Genotype 
One Shot TOP10   Invitrogen/ C4040-03   F- mcrA (mrr-hsdRMS- 
Chemically Competent E.coli     rBC) 80lacZ M15  
         lacX74recA1 ara 139 
         (ara-leu)7697  galU galK 
         rpsL (StrR)  endA1 nupG 




 One Shot ccdB Survival™  Invitrogen/ C7510-03   F- mcrA ∆(mrr-hsdRMS-2 
T1R Competent Cells       mcrBC) Φ80lacZ∆M15 
         ∆lacX74 recA1 ara∆139 
         ∆(ara-leu)7697 galU galK 
         rpsL (StrRendA1 nupG 
         tonA::Ptrc-ccdA 
2.7 Growth media 
All growth media listed here were sterilized by autoclaving 
Media         Composition 
LB (Luria-Broth)      10 g NaCl, 10 g tryptone,                                                                  
       5 g yeast extract, to 1 L with dd H2O 
       pH 7.0 with 5N NaOH 
      
DMEM-LG       10.03 g DMEM-LG, 3.7 g NaHCO3                                                                                               
(Dulbecco’s Modified Eagle Medium-   to 1 L with dd H2O            
Low Glucose)        
 
DMEM-HG      13.44 g DMEM-HG, 3.7 g NaHCO3 
(Dulbecco’s Modified Eagle Medium-  to 1 L with dd H2O            
High Glucose)                                                                                                      
 
RPMI 1640      10.39 g RPMI-1640, 2 g NaHCO3 
       to 1 L with dd H2O 
2.8 Solutions and buffers 
Solution        Composition  
      
Agarose gel electrophoresis loading buffer (6X) 00.09% bromophenol blue,   
       60.0% glycerol, 60.00 mM EDTA            
                                                                                              
 Ampicillin stock solution                                         500 mg/ml in dd H2O 




Ethidium bromide stock solution                              10 mg/ml in dd H2O 
 
Glycine solution                                                         0.10 M glycine-HCl, pH 3 
 
Kanamycin stock solution                                         50 mg/ml in dd H2O 
 
MR solution (Mammalian Ringer)         130 mM NaCl, 4 mM KCl, 1 mM CaCl2,
       1 mM MgSO4,  20 mM HEPES, 
       1mM NaH2PO4, 18 mM glucose, pH 7.4 
 
Na+ free MR      130 mM TMACl, 4 mM KCl,1 mM CaCl2 
(Sodium free Mammalian Ringer)   1 mM MgSO4, 1mM TMAPO4, 20 mM 
       HEPES, 18 mM glucose, pH 7.4 
 
SDS-PAGE electrophoresis running buffer (10X)  30.30 g Tris base, 144.0 g glycine,  
       10.0 g SDS, to 1 L with dd H2O 
 
SDS-PAGE stacking gel buffer    0.5 M Tris-HCL pH 6.8,  
       0.4 % SDS in dd H2O 
 
SDS-PAGE separation gel buffer    1.5 M Tris-HCl pH 8.8 
       0.4 % SDS in dd H2O 
 
SDS-PAGE sample buffer (2X)   0.125 M Tris-HCl, pH 6.8, 4.0 % SDS 
       20 % glycerol (v/v), 10 mM DTT 
       0.02 % bromophenol blue 
 
TAE buffer (10X)      0.4 M Tris acetate, 10 mM EDTA, pH 8.3 
 
Lysis buffer       400 mM NaCl, 1 mM EDTA 
       10 mM Tris/HCL pH 8,  
       0.1 % Triton X 100 
 




Western Blot buffer      25 mM Tris base, 192 mM glycine, 
       20 % (v/v) methanol 
2.9 Chemicals  and Enzymes  
Chemicals were bought from Sigma-Aldrich (Hamburg, Germany), Applichem (Darmstadt, 
Germany) Merck (Darmstadt, German) and Calbiochem (Gibbstown, USA). Radioactive 
chemicals were bought from Amersham Bioscience (Freiburg, Germany). 
Restriction endonucleases were purchased from New England Biolabs Inc (Beverly, MA, 
USA) or MBI Fermentas (Vilnius, Lithuania). T4 DNA ligase was purchased from 
Boehringer Mannheim (Mannheim, Germany). 
2.10 Software  
Listed below are the software and online servers used to analyze raw sequence data, perform 
sequence alignments and primer design. 
Software  
Program  Use  Reference  
Chromas  sequence reading program  Technelysium Pty Ltd  
Microsoft Excel  evaluation of uptake experiments  Microsoft Corporation  
SigmaPlot  statistical analyses Jandel Corporation 
Reference Manager  managing of bibliographic references  Wintertree Software Inc  
Online sequence analysis servers  
Program  Use  Reference  
Entrez Browser  sequence retrieval  http://www.ncbi.nlm.nih.gov/Entrez/  
MAP  multiple sequence alignments  http://genome.cs.mtu.edu/map.html  
Blast  Sequences alignments  http://www.ncbi.nlm.nih.gov/BLAST/ 
ClustalW  Sequences alignments http://www.ebi.ac.uk/clustalw/ 





Appliance   Model   Manufacturer 
Centrifuges   Biofuge fresco Heraeus (Osterode, Germany) 
                                               5417R   Eppendorf (Hamburg, Germany) 
Circulating water baths D8   Haake (Karlsruhe, Germany) 
Gel chamber   Midi   MWG-Biotech (Ebersberg, Germany) 
Gel documentation  Gel Print 2000 I Biophotonics (Ann Arbor, MI, USA) 
Blot imaging   LAS 3000 Imager Fujifilm (Duesseldorf, Germany) 
Microplate reader  Model 680  Bio-Rad (Munich, Germany) 
Microwave   Privileg 8017  Quelle Schickedanz (Fuerth, Germany) 
pH meter   pH-Meter 611  Orion Research Inc (Beverly MA, USA) 
Real time PCR system Mx3005p  Stratagene (Waldbronn, Germany) 
Scintillation counter  1500 Tri-Carb  Packard Instrument Co (Meridien, USA) 
Shaking incubator  3031   GFL (Burgwedel, Germany) 
Spectrophotometer  GeneQuant II  Pharmacia (Uppsala, Sweden) 
Thermocycler   PTC-200  MJ Research (Watertown MI, USA) 
UV transilluminator  TM40   UVP Inc (Upland, CA, USA) 
Vortex    MS1   IKA (Staufen, Germany) 
                               





3.1 Cell culture 
3.1.1 Suspension cells 
Lymphoma cell lines were grown in 100 ml cell culture flasks at 37°C with 5% CO2. Cells 
were grown in supplemented RPMI-1640 media and for passaging the suspension cells, 5 ml 
of cell culture was diluted with 20 ml medium in the culture flasks. 
3.1.2 Adherent cells 
CHO and HEK-293 cells were grown in 100 mm culture plates at 37°C with 5% CO2. Cells 
were cultivated routinely in culture medium (supplemented DMEM-LG and DMEM-HG, 
respectively) and passaged 1:5 every third day. Before splitting, medium was removed and 
cells were rinsed once with PBS. Then, 2.5 ml of pre-warmed EGTA-containing “milieu C” 
was added per 100 mm culture dishes. After incubation at 37°C for 2-3 minutes (time required 
for detachment the cells from the plate), 2.5 ml of complete medium per culture dish was 
added and the cell suspension transferred into a sterile 15 ml Falcon tube. The cells were 
collected by centrifugation at room temperature at 1000 rpm for 5 minutes. Supernatant was 
aspirated and cells resuspended 1:2 in fresh complete medium, counted using the 
Hemacytometer (before counting, 20 µl of cell suspension was diluted with 180 µl of medium 
for better accuracy) and seeded in the required density. Since the HEK-293 cells come off the 
plate easily, culture dishes were coated with polylysine (Sigma). Therefore, 500 µl of 
polylysine solution was pipetted into each well of 24 well plates shortly before seeding, 
aspirated after a 5 minutes and the plates were allowed to dry before seeding the cells. For 
transport experiments, cells were plated into the 24 well plates at the density of 2 x 105 cells 
per well up to 72 hours before the experiment.  
3.2 RNA Preparation 
Total RNA isolation from cell lines and patient samples was done to carry out RT-PCR and 
Real-time PCR using the products. TRIZOL Reagent is a mono-phasic solution of phenol and 
guanidine isothiocyanate. TRIZOL Reagent maintains RNA integrity during sample 
homogenization, while lysing cells and dissolving cell components. The addition of 
chloroform to the homogenized sample, followed by centrifugation separates the sample 




solution into two phases: aqueous and organic. The aqueous phase contains the RNA and this 
RNA is recovered by precipitation with isopropyl alcohol.  
Homogenization of samples was done in 1 ml TRIZOL. The nucleoprotein complexes were 
incubated at room temperature for 5 minutes. This was followed by the addition of 0.2 ml 
chloroform, shaking for 15 seconds and incubation at room temperature for 10 minutes. 
Centrifugation of the mix was done at 12000 x g, which separated the mixture into the lower 
red (phenol-chloroform phase) (contains proteins), the interphase (contains DNA) and the 
colourless upper aqueous phase (contains RNA). The RNA-containing aqueous phase was 
transferred to a fresh tube and RNA precipitated using 0.5 ml isopropanol per 1 ml TRIZOL. 
Samples were kept on ice for 15 minutes and centrifuged for 10 minutes at 4°C at 12000 x g. 
The supernatant was removed and the RNA pellet (formed as a gel like precipitate) washed 
with 75% ethanol by vortexing and subsequent centrifugation for 8 minutes at 7500 x g at 
4°C. The excess isopropanol was removed from the RNA pellet by air drying for 10 minutes 
and resuspended in RNase free water. 
3.3 cDNA Synthesis 
Complementary DNA (cDNA) sequences are derived from the coding sequences of specific 
genes using random primer. The viral RNA-dependent DNA polymerase, called reverse 
transcriptase, uniquely synthesizes DNA products from primed RNA templates. The first step 
includes the purification of mRNA. Nonspecific template primers (random primers) may then 
be used to initiate cDNA synthesis.  
2 µg RNA was mixed with 1 µl Random primer and this mixture was made up to 14 µl with 
dd H2O, followed by an incubation of 10 minutes at 70°C and a further incubation of 2 
minutes at 4°C. Following incubation, a mixture containing 4 µl 5X RT buffer, 1 µl 10 mM 
dNTPs and 1 µl MuLV enzyme (200 U/ml) was added to each reaction mix. The reaction mix 
was incubated at 37°C for 1 h, followed by 10 minutes incubation at 70°C to inactivate the 
MuLV enzyme. 
3.4 Polymerase chain reaction 
The polymerase chain reaction (PCR) is a three step process which allows the amplification of 
a specific DNA region. Each cycle consists of: DNA template denaturation, primer annealing, 
and primer extension. The reaction, carried out in a thermal cycler, involves the denaturation 




of the double helix at 94°C, followed by a lowering of temperature to allow the gene specific 
primers to anneal. The primers chosen are complementary to the flanking region of the target 
DNA. The annealing temperature is optimized depending on the length and base sequence of 
the annealing primers. The third step is the extension step in which the heat stable DNA 
polymerase catalyzes DNA synthesis using the target DNA as template and dNTPs provided 
in the reaction mix as building units. Extension time depends on the length of the target DNA. 
Each PCR cycle results in the formation of two new DNA strands identical to the target 
region defined by the primers. 
Each 50 µl reaction mix contained 5 µl of RT-PCR product (template cDNA), 1 µl of each 
gene specific primer (100 pmol/µl), 8 µl dNTPs (10 mM each), 5 µl buffer (10X buffer), 1 µl 
Taq polymerase (5 U/µl) and 29 µl double distilled water (dd H2O). PCR conditions used 
were: 3 minutes at 94°C, 30 cycles of 40 seconds denaturation at 94°C, 50 seconds annealing 
at the specific annealing temperature, 1 minute extension at 72°C. The 30 cycles were 
followed by a final step of 5 minutes at 72°C. 
3.5 Real-time PCR  
Real-time PCR allows the detection of the increase in the amount of DNA as it is amplified. 
The TaqMan probe used in our studies consists of two fluorophores. While the probe is 
attached or unattached to the template DNA; and before the polymerase acts, the quencher 
fluorophore, found at the 3’ end of the probe reduces the fluorescence from the reporter 
fluorophore, found at the 5’ end of the probe. Taq polymerase action results in the 
amplification and subsequent removal of the TaqMan probe from the template DNA. This 
results in a separation of the quencher from the reporter, allowing the reporter dye to emit its 
energy, which is then quantified by the computer.  
For TaqMan based PCR, the reaction mix included 2X reaction buffer, 20X TaqMan probe, 5 
µl of cDNA, nuclease free H2O to a volume of 25 µl. The thermocycler was programmed as 
follows: 1 cycle with 2 min at 52°, 10 min at 95°, followed by 40 cycles including 15 s at 95° 
and 1 min at 61°C. ∆Ct evaluation (CT target – CT reference)] was done for the analysis of TaqMan 
based real-time PCR data. GAPDH was used as an endogenous control (as an active 
reference). Normalization of gene quantification was done for differences in the amount of 
total nucleic acid added to each reaction. 
 




3.6 Agarose gel electrophoresis 
Agarose gel electrophoresis is a method to separate DNA strands by size. The size of the 
strands is estimated by comparison to known fragments. Negatively charged DNA molecules 
are pulled through the agarose matrix using an electrical field. Migration speed of a DNA 
fragment in the gel is inversely proportional to its size. Increasing the agarose concentration 
of a gel reduces the migration speed and enables separation of smaller DNA molecules. The 
central dye used is ethidium bromide, which fluoresces under UV light when intercalated with 
DNA. DNA fragments run in an ethidium bromide-treated agarose gel enables the 
visualization of distinct bands under UV light. 
For preparing 1% agarose gel, 1.0 g agarose were dissolved in 100 ml TBE buffer by heating 
the mix in a microwave. The solution was allowed to cool down before adding 3 µl ethidium 
bromide stock solution (1 mg/ml). The mix was poured in a casting unit and a spacer comb 
placed. Samples were prepared by adding 5 µl of the agarose gel loading buffer to 20 µl of 
each sample under test. 5 µl of the appropriate molecular weight marker was loaded alongside 
each electrophoretic run. The electrophoresis was done at 100 V for approximately 50 
minutes after which the DNA bands were visualized under the UV transilluminator. 
3.7 Plasmid Purification 
A clone positive for the insert was aseptically transferred to 5 ml or to 200 ml sterile LB 
medium containing the resistance antibiotic (100 µl/ml for ampicillin and 50 µl/ml for 
kanamycin) and allowed to grow overnight at 37°C, 250 rpm. Plasmids were prepared from 
the bacterial cultures using the CompactPrep Plasmid Midi Core Kit for midi preps and the 
Nucleospin Plasmid kit for mini preps. 
3.7.1 Plasmid Midi-prep 
The CompactPrep Plasmid Midi Core Kit from Qiagen is an anion exchange resin-based 
plasmid purification kit. Bacterial cells are first lysed through the alkaline lysis method using 
a combination of NaOH and SDS (Buffer P2). SDS solubilizes the cell membrane lipids and 
proteins resulting in the release of the cell contents, while NaOH results in DNA and protein 
denaturation. The addition of acidic potassium acetate (Buffer P3) results in the precipitation 
of potassium dodecyl sulphate (KDS) where denatured proteins, genomic DNA and cellular 
debris become entrapped in this salt-detergent complex. Plasmid DNA being smaller and 




covalently closed, renatures correctly and remains in the lysate solution as it is neutralized. 
The resulting supernatant is filtered and loaded on a QIAfilter cartridge. The eluted DNA is 
washed following which it is loaded to the CompactPrep column. The DNA is bound as a thin 
layer and is subsequently eluted using Tris.Cl buffer. 
A 100 ml overnight bacterial culture was centrifuged at 6000 x g for 15 minutes. The 
supernatant was decanted and the pellet resuspended in 5 ml of the provided Buffer P1 (ice 
cold with RNase A). The homogenized lysate was transferred to a fresh 50 ml Starstedt tube 
and alkaline lysis done by adding 5 ml of Buffer P2 added. The mixture was shaken well and 
incubated at room temperature for 5 minutes. The lysate was neutralized by adding 5 ml 
Buffer P3. The lysate was then poured into the barrel of the QIAfilter Cartridge and incubated 
at room temperature for ten minutes. The lysate from the cartridge was passed into a 50 ml 
tube. The cleared lysate was washed with 5 ml Buffer BB. This mix was transferred to the 
CompactPrep column. The DNA was washed with 700 µl Buffer PE. The plasmid DNA was 
eluted using 200 µl Buffer EB.  
3.7.2 Plasmid Mini-prep 
The NucleoSpin Plasmid from Macherey-Nagel kit is based on the use of single solution for 
cell suspension, alkaline lysis as well as for DNA binding to a silica-based membrane. A 
high-salt buffer is used to allow only DNA to be adsorbed to the silica membrane. 
Precipitated proteins, RNA and metabolites flow through the column. The bound DNA is 
eluted in low-salt buffer. 
A 5 ml bacterial culture was centrifuged at 11,000 x g for 5 minutes and the supernatant 
decanted. The pellet was resuspended in 250 µl of the ice-cold lysis buffer (Buffer A1) and 
the suspension made homogeneous by vortexing. 250 µl  Buffer A2 was added to the the 
homogenized lysate and the mixture incubated for 5 minutes at room temperature, following 
which 300 µl Buffer A3 was added. Lysate clarification was done by centrifuging the mix for 
5 minutes at 11,000 x g and the supernatant loaded onto a NucleoSpin Plasmid Column. The 
loaded spin column was centrifuged for 1 minute, washed with 600 µl of the diluted wash 
buffer (Buffer A4) and centrifuged again. The flow through was discarded and the spin 
column dried by centrifugation at full speed for 1 minute. Elution of the bound DNA was 
done adding 50 µl of the provided elution buffer, Buffer AE to the centre of the membrane 
and centrifuging at maximum speed for 1 minute. 




3.8 DNA Sequencing 
Sequencing was performed by automated dye terminator cycle sequencing method (Applied 
Biosystems), at a centralized facility within the university. In this method a premix solution, 
containing four dideoxynucleotides (ddNTPs), each labeled with a different fluorescent dye, 
and unlabelled deoxynucleotides is mixed with the template DNA and one sequencing primer. 
The fluorescence of dye-containing polynucleotides was stimulated by 40 mW argon laser 
(488 nm and 514 nm) and the fluorescent signal was identified by the detector system of the 
DNA sequencer (automatic sequencer: ABI Prism, Applied Biosystems) and quantified.  
300-500 ng DNA were mixed with 10 pmol primer, 6X SeqMix, 5X Buffer and the volume 
made up to 10 µl with dd H2O. The sequencing reaction comprised 25 cycles of: 96°C for 30 
seconds, 50°C for 50 seconds and 72°C for 4 minutes. Amplification products were 
precipitated by the addition of 50 µl of 100 % ethanol, 1 µl of 3 M Na acetate and 1 µl of 125 
mM EDTA, followed by 5 minutes’ incubation. After the incubation, centrifugation of the 
samples was done for 20 minutes at 14,000 U. Supernatant was discarded carefully, without 
disturbing the pellet. The product was washed with 250 µl of 70 % ethanol and centrifugation 
for 10 minutes at 14000 U. Supernatant was removed completely and pellet was air dried and 
finally resuspended in 30 µl of Hi-Di. The sequence was assembled and analyzed with various 
software packages, as listed in Section 2.10.  
3.9 Generation of stable transfected cell lines 
NaDC3- FlpIn T-Rex HEK 293 cell line was prepared using Gateway Cloning Technology. 
This uses site-specific recombination properties of bacteriophage lambda. Four steps are 
involved: The first step is the generation of an entry clone where the gene of interest is 
introduced into a donor vector. The second step includes making a destination vector with a  
reading frame cassette containing the appropriate recombination sites. The generation of the 
expression vector involves recombining the donor vector and the destination vector to express 
the gene of interest, in this case NaDC3. The final step is the stable transfection of the Flp-In 
T-Rex HEK 293 cells with the generated expression vector.  
3.9.1 Generation of the entry clone 
Generation of the Entry Clone involved carrying out a BP Reaction, so named because of the 
attachment B and the attachment P sites involved. The BP Reaction transfers the gene in the 




Expression Clone (between attB sites) into a Donor vector (containing attP sites), to produce 
a new Entry Clone (attL sites) which was selected on Kanamycin plates. This reaction is 
catalyzed by the BP Clonase mix of recombination proteins. 150 ng of attB-site containing 
NaDC3 Expression Clone was mixed with 150 ng/µl pDONR 221 and the reaction volume 
made up to 8 µl with TE buffer (pH 8). 2 µl BP Clonase II enzyme mix was added and the 
reaction mixture incubated for 1 hour at 25°C. To terminate the reaction, 1 µl Proteinase K 
was added and sample incubated at 37°C for 10 minutes. The BP reaction was then 
transformed into One Shot Phage Resistant Cells and plated onto kanamycin (50 µg/ml) 
plates. Once a gene is flanked by attL sites as an Entry Clone, it can be transferred into new 
expression vectors by recombination with Destination Vectors (via the LR Reaction).  
3.9.2 Generation of destination vector 
A tetracycline inducible vector was converted into a Destination Vector using the Gateway 
Vector Conversion System from Invitrogen. 5 µg plasmid vector was digested using Eco RV 
restriction enzyme. Following the removal of 5’ phosphates, DNA was adjusted to a final 
concentration of 50 ng/ µl. Separate ligation mixtures were set up for the three different 
reading frame cassettes and contained: 50 ng dephosphorylated vector, 2 µl 5X T4 DNA 
ligase buffer, 2 µl Gateway reading frame cassette (10 ng), 1 µl T4 DNA ligase (I U/µl) and 
the volume made up to 10 µl with dd H2O. The ligation mixture was incubated at room 
temperature for 1 hour, followed by transformation into ccdB Survival Competent Cells and 
finally plated on chloramphenicol (30 µg/ml) plates.  
3.9.3 Generation of expression vector 
The LR Reaction is a recombination reaction between an Entry Clone and a 
DestinationVector mediated by the LR Clonase mix of recombination proteins. This reaction 
transfers DNA segments from the Entry Clone to the Destination Vector, to create an 
Expression Clone. 150 ng Entry Clone was mixed with 150 ng/µl Destination vector and the 
volume made up to 8 µl with TE Buffer (pH 8). 2 µl LR Clonase II enzyme mix was added 
and the reaction mixture incubated for 1 hour at 25°C. To terminate the reaction, 1 µl 
Proteinase K was added and sample incubated at 37°C for 10 minutes. The LR reaction was 
then transformed into One Shot Phage Resistant Cells and plated onto selective ampicillin 
(100 µg/ml) plates. 
 




3.9.4 Transient transfection into Flp-In T-Rex HEK-293 cells 
We carried out transient transfection to determine the functionality of the generated 
expression vector. Flp-In T-Rex HEK- 293 cells were grown overnight at a concentration of 2 
x 105 cells/ well. Transfection medium was prepared for each well by adding 2 µl 
Lipofectamine to 48 µl medium without FCS. In another tube, 1 µg plasmid DNA was mixed 
with medium without FCS to give a final volume of 50 µl. The two tubes were incubated for 5 
min at room temperature, followed by mixing the two and further incubation of 20 minutes. 
400 µl medium without FCS was added to each well, followed by 100 µl of the transfection 
mix. Cells were incubated for 4-6 h at 37°C and the medium then changed to that containing 
FCS. Cells were used for uptake assays the following day. 
3.9.5 Stable transfection into Flp-In T-Rex HEK -293 cells 
The final step involved introducing the expression vector into Flp-In T-Rex HEK -293 cells. 
The expression vector containing NaDC3 gene was co-transfected with another plasmid, 
pOG44, into cells. pOG44 expresses the Flp recombinase while the expression vector and the 
Flp-In cells express the FLP Recombination Target, FRT site. FRT sites serve as recognition 
and cleavage sites for Flp recombinase from pOG44 and allow recombination to occur. The 
hygromycin resistance gene in the expression vector lacks a promoter and the initiation 
codon; the action of Flp recombinase brings these into the correct frame. The stable cell line 
is thus resistant to hygromycin B. 6 x 105 cells were seeded into one well of a 6-well plate and 
incubated overnight. Co-transfection of the NaDC3 Expression Vector and pOG44 in 1:9 ratio 
was done using Lipofectamine. Following transfection, cells were incubated at 37°C for 5 
hours and medium changed with that containing 10% FCS. After another overnight 
incubation, cells were transferred to a 100 mm dish and incubated to enable attachment for 5-
6 hours, following which Hygromycin B was added (175 µg/ml). Cells were allowed to grow 
and medium changed after one week. After another 14 days, stable transfected colonies were 
picked and transferred to a 96-well plate. When the colonies were confluent, they were further 
transferred to 24-well, 60 mm dish and ultimately to a 100 mm dish.  
3.10 Transformation into competent cells 
The process by which exogenous DNA is introduced into bacterial cells is known as 
transformation. Transformed bacterial cells with plasmids having an appropriate origin of 
replication recognized by the host DNA polymerases offers a method for plasmid 




propagation. Bacteria that are capable of transformation are referred to as competent bacteria. 
Competency can be induced by a manipulation that causes the outer membrane of the bacteria 
to partially lose its integrity. Calcium chloride treatment compromises the outer membrane of 
some E.coli strains. The resulting E.coli is called chemically competent and can be 
transformed. 
1 µl of the ligation mix were added to 50 µl of partially thawed chemically competent E.coli. 
After incubating the mix for 30 minutes on ice, it was transferred to a 37°C heat block for 30 
seconds (heat shock). 250 µl of pre-warmed SOC medium was added to the transformation 
mix. The mixture was incubated at 250 rpm, 37°C for 60 minutes to allow the expression of 
the resistance gene under non-selective conditions. 100 µl of the mix was aseptically spread 
on a pre-warmed agar plate containing the specific antibiotic. The plate was incubated 
overnight at 37°C to allow the growth of bacteria successfully transformed with the plasmid. 
3.11 Transport studies   
Adherent CHO or HEK-293 cells were cultured in 24 well plates and grown until 90 -100% 
confluence. Directly before uptake, cells were washed three times with 1 ml of Mammalian 
Ringer solution, pre-warmed to 37°C. The transport media was pre-warmed Mammalian 
Ringer solution, containing radioactively labeled substance (1 µM [3H]MPP or 18 µM 
[14C]succinate) and the particular cytostatic (100 µM). 200 µl uptake solution was carefully 
added to each well and cells incubated in the transport media at room temperature for 5 
minutes.  After incubation, cells were washed with ice cold PBS solution and lysed by the 
addition of 500 µl 1 N NaOH for 20 min. After complete lysis, the solution was neutralized 
with 1 N HCl, transferred to scintillation vials and 2.5 ml Lumasafe scintillation solution 
added to each sample. The [3H] or [14C] content was measured in a scintillation counter 
(TriCarb 1500 Packard) over 5 minutes. 
 
3.11.1 Apparent Km determination 
Apparent Km determination was done to determine substrate affinity of specific transporters. 
The apparent Km of a substrate is determined in the presence of a competitive inhibitor at a 
defined concentration.  
   




CHO cells expressing OCT1 and OCT2 were measured for 1 µM [3H]MPP and 20 µM 
[3H]MPP uptake over 5 min in Mammalian Ringer in the presence of increasing 
concentrations of unlabelled irinotecan (0-20 µM). For apparent Km determination of 
mitoxantrone and paclitaxel for OCT1, concentrations of 0-140 µM unlabelled cytostatic were 
used.  
3.12 Cytotoxicity studies 
3.12.1 MTT assay 
A colorimetric assay, the MTT assay is used for measuring the activity of the mitochondrial 
enzyme, mitochondrial reductase, which reduces the yellow MTT (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) to formazan, giving a purple colour. The insoluble 
formazan is diluted in hydrochloric acid and the absorbance measured using a 
spectrophotometer. It is used to determine cell cytotoxicity on application of different 
substances, which would disrupt metabolic functions.  Since the reduction of MTT to 
formazan takes places only by active reductase enzymes, the test is a measure of active, viable 
(living) cells.  
3.12.1.1 Adherent cells 
6-well plates were seeded with 0.5 x 103 cells and grown 24 hours to 50- 70% confluence. 
The cells were incubated with desired substances (100 µM irinotecan/ mitoxantrone/ 
paclitaxel, 2 mM TEA, 100 µM corticosterone, 100 µM irinotecan/ mitoxantrone/ paclitaxel + 
2 mM TEA and 100 µM irinotecan/mitoxantrone/ paclitaxel + 100 µM corticosterone) and 
incubated for 15 minutes at 37°C. Following this incubation, cells were washed with medium 
and incubated overnight. Cell viability was determined by adding 750 µg/ ml MTT to each 
well and a further incubation of 2 hours at 37°C. Purple formazan crystals were then diluted 
in acidified isopropanol (96% isopropanol + 4% 1 N HCl) and absorbance was measured at 
595 nm.  
3.12.1.2 Suspension cells 
2.5 x 104 cells/well were seeded in round-bottom 96-well plates (Sarstedt) and incubated 
overnight. Cells were then treated with different substances (same as for adherent cells) and 
incubated at 37°C.  After 15 minutes incubation, cells were centrifuged (500 rpm, 10 min) and 
incubated in fresh medium. After 24 h incubation, cells were centrifuged and the pellet 




resuspended in MTT solution (750 µg/ ml in each well). Cells were incubated for 2 h at 37°C 
and the reaction stopped by adding an equal volume of acidified isopropanol. The amount of 
reduced MTT was assayed by measuring the absorbance at 595 nm using the Microplate 




The incorporation of [3H]thymidine into cellular DNA is one of the most common cell 
proliferation assays. Drug effects are quantitated in the thymidine incorporation assay by 
measuring inhibition of deoxyribonucleic acid (DNA) synthesis by the proliferating cell 
population following exposure to anticancer drugs. 
OCT expressing CHO cells were incubated for 15 min with cytostatics (100 µM irinotecan/ 
mitoxantrone/ paclitaxel, 2 mM TEA, 100 µM corticosterone, 100 µM irinotecan/ 
mitoxantrone/ paclitaxel + 2 mM TEA and 100 µM irinotecan/mitoxantrone/ paclitaxel + 100 
µM corticosterone). After the incubation, cells were washed twice with medium and 
incubated 4h at 37°C. Radioactive thymidine was diluted with the medium to a final activity 
of 0.2-1 µCi/ml. After 15 min incubation at 37°C, cells were fixed with 5% trichloroacetic 
acid for 30 min at 4°C. The plate was then washed twice with 500 µl of ice cold PBS and once 
with 500 µl of ice cold 95% ethanol. For the full solubilisation of genomic DNA, the plate 
was incubated with 500 µl of 1 N NaOH for 2 hours. Following lysis, the solution was 
neutralized with 500 µl of 1 N HCl and transferred to scintillaion vials together with 2.5 ml of 
Lumasafe scintillation fluid. Incorporated radioactivity was measured in the scintillation 
counter (TriCarb 1500 Packard). 
3.13 SDS-PAGE 
SDS-PAGE is an analytical technique used for the separation of proteins based on their 
molecular weights. The anionic surfactant sodium dodecyl sulphate and the treatment of 
samples with reducing agents like dithiothreitol (DTT) or ß-mercaptoethanol, which causes 
the denaturation of the protein, imparts a uniform negative charge on the protein samples. The 
separation during electrophoresis thus takes place based on their mass/ charge ratio. A 
stacking gel is normally loaded onto a separating gel in a ‘discontinuous’ gel, where the pH 
conditions of the stacking gel results in the samples to stack at the starting point above the 
separating gel. The protein samples are then resolved in the separating gel due to differences 
in their molecular weights. 




The composition of the stacking and separating gel for two gels is given in Table 3.1. 50-100 
µg of the sample was mixed with 5X sample buffer containing β-mercaptoethanol. The 
samples were boiled at 95°C for 10 minutes and loaded onto the discontinuous SDS 
polyacrylamide gel cast in miniprotean 3 system. The prestained molecular weight marker 
(Fermentas) was loaded in a separate lane. The electrophoretic run was allowed to occur at a 
constant current of 20 mA with maximum voltage set at 300 V. 
Table 3.1 Composition of Stacking and Separating gels used for SDS-PAGE (for two 
gels) 
Component Stacking gel Separating gel 
 4% 8% 10% 
30% acrylamide/bisacrylamide 666 µl 3.17 ml 3.96 ml 
dd H2O 3.04 ml 5.83 ml 5.04 ml 
Stacking gel/Separating gel buffer 
(4x)+ 0.4% SDS 
1.25 ml 3.0 ml 3.0 ml 
TEMED 5.0 µl 6.0 µl 6.0 µl 
10% APS 25.0 µl 60.0 µl 60.0 µl 
 
3.14 Western blotting 
Western immunoblotting allows the determination of a single protein from a mixture of 
proteins and also gives an estimate on the size of the protein. The method relies on the use of 
a high-quality primary antibody directed against the protein of interest. The primary antibody 
is detected using an enzyme-conjugated (eg. peroxidase-conjugated) secondary antibody 
raised against the Fc portion of the primary antibody. When the enzyme substrate is applied, 
the conjugated peroxidase catalyzes a light emitting reaction that can be visualized after 
developing an X-ray film exposed to the membrane. A three step process, western 
immunoblotting involves the separation of a mixture of proteins in SDS-PAGE in the first 
step. The second step is the transfer of resolved proteins from the gel onto a membrane 
support (eg. Polyvinylidene difluoride, PVDF) using electrophoresis. The final step involves 
the incubation of the membrane with specific antibodies and its subsequent detection for the 
specific protein. 




3.14.1 Transferring resolved proteins from the gel to a PVDF membrane 
Following electrophoresis, the gels were equilibrated in chilled (4°C) Western blot buffer. A 
cut-to-size PVDF membrane was briefly immersed in methanol, washed in dd H2O and then 
equilibrated in the blotting buffer. The gel and the activated membrane were sandwiched 
between fiber pads and filter papers previously soaked in blotting buffer. The assembled gel/ 
blot sandwich was placed in the Bio-Rad blotting cassette holder and placed in the Bio-Rad 
blotting tank. The tank was filled with the blotting buffer and electrophoresis run at a constant 
voltage of 100 V for 60 minutes. 
3.14.2 Protein detection on Western blots 
After completion of transfer, the PVDF membrane was briefly washed in 1X PBS/ 0.05% 
Tween to remove residual methanol from the blotting buffer. The membrane was incubated 
for 1 hour in 5% skimmed milk (in 1X PBS/ 0.05% Tween) at room temperature to block 
nonspecific binding of the antibodies. The primary antibody solution was then applied to the 
membrane. The 1 ml solution covered the entire membrane, the membrane sealed with 
parafilm and incubated overnight at 4°C. 
Following overnight incubation, the membrane was washed thrice with washing buffer (1X 
PBS/ 0.05%Tween), at intervals of 10 minutes. Incubation with peroxidase conjugated 
secondary antibody (in 1X PBS/ 0.05% Tween) was done for 2 hours at room temperature. 
This was followed by three washing steps at 10 minutes’ intervals. For detection, 750 µl ECL 
solution A/ solution B (1:1) mix were applied to each membrane and incubated for 5 minutes. 
The blots were developed using the LAS3000 Imager (Fujifilm). 





4.1 RT-PCR analysis and quantification of transporter expression in lymphoma cell 
lines and in Chronic Lymphocytic Leukaemia patient samples 
As a first, non-quantitative approach, RT-PCR analysis was done for selected transporter 
proteins. Using previously designed primers, six lymphoma cell lines as well as lymphocytes, 
termed here “healthy lymphocytes”, purified from healthy blood samples (obtained from the 
blood bank) were used for this analysis. The six lymphoma cell lines used included four B-
lymphoma cell lines: Karpas-422, Raji, SUDHL-4 and L-428 and two T-lymphoma cell lines: 
Jurkat and HUT-78. The cell lines were all kindly provided by Prof G. Wulf at the Dept. of 
Haematology and Oncology, University Klinikum, Goettingen.  
The screening of SLC transporters in six lymphoma cell lines by RT-PCR was followed by 
real-time PCR analysis to evaluate and quantify the expression of selected transporters in the 
lymphoma cell lines as well as in samples from patients of Chronic Lymphocytic Leukaemia, 
CLL. CLL patient samples were divided into groups of seven and each group was used for 
quantitative analysis of one transporter family. For real-time analysis, the expression in 
normal, healthy lymphocytes was set to zero and relative expression of samples analyzed after 
normalization with GAPDH. Mean results were calculated from three independent 
experiments with two repeats each for the cell lines. For CLL patient samples, mean results 
were calculated from two independent experiments with two repeats each. 
4.1.1 SLC family transporters not expressed in lymphoma cell lines 



















4.1.2 SLC family transporters expressed in lymphoma cell lines 
4.1.2.1 Expression of SLC7 family transporters 
Each cDNA preparation was controlled using GAPDH amplification.  
The L-amino acid transporter 1, LAT1 (SLC7A5), was expressed in all the lymphoma lines 
tested (Figure 4.1). Three B-lymphoma cell lines, Karpas-422, Raji and L-428 had similar 
expression levels, also comparable to LAT-1 expression in the two T-lymphoma cell lines, 
Jurkat and HUT-78. LAT-1 expression in the fourth B- lymphoma cell line, SUDHL-4 was 
slightly lower than the other cell lines, but this expression level was comparable to healthy 
lymphocytes, where LAT-1 expression also seemed lower.  
            









           Fig 4.1  RT-PCR screening of SLC7 family transporters in lymphoma cell lines.  
 K: Karpas-422, R: Raji, S: SUDHL-4, J: Jurkat, H: HUT-78, L: L-428, HP-1:  Healthy 
 person  sample-1, +: positive control, -: negative control. Also shown is a representative 
 GAPDH amplification, used as cDNA quality control. 
 
 




4.1.2.2 Expression of SLC16 family transporters 
The monocarboxylate transporters exhibited high expression levels in lymphoma cell lines 
(Figure 4.2). Among the MCT members, the highest expression was observed for MCT1 
(SLC16A1), with all six cell lines exhibiting a much stronger expression than in healthy 
lymphocytes.  
MCT2 was expressed at comparatively lower levels than MCT1. While four cells lines, 
Karpas-422, Raji, Jurkat and HUT-78 exhibited similar expression levels, MCT2 expression 
was lower in SUDHL-4. The B- lymphoma cell line, L-428 showed an extremely low 
expression of MCT2. The expression of MCT2 was also lower in healthy lymphocytes  than 
in five cell lines.  
 Among the cell lines, L-428, Karpas-422 and Jurkat demonstrated the strongest expression of 
MCT4. SUDHL-4 and HUT-78 had comparable expression to the healthy lymphocytes 
samples tested. The B-lymphoma cell line, Raji, had a lower expression of MCT4.  
 














 Fig 4.2  RT-PCR screening of SLC16 family transporters in lymphoma cell lines. K: 
 Karpas-422, R: Raji, S: SUDHL-4, J: Jurkat, H: HUT-78, L: L-428, HP-1: Healthy person 
 sample-1, HP-2: Healthy person sample- 2, +: positive control, -: negative control.  
 
Since MCT4 exhibited more expression changes within the cell lines, only MCT4 (SLC16A3) 
was quantified using real-time PCR in lymphoma cell lines and CLL patient samples. In 
general, MCT4 was expressed at much higher levels in lymphoma cell lines than in healthy 
lymphocytes, with Raji and SUDHL-4 being exceptions where the expression was lower. In 




healthy lymphocytes, MCT4 appeared at cycle 30 while it appeared at cycles 25, 38, 38, 28, 
30 and 23 in Karpas-422, Raji, SUDHL-4, Jurkat, HUT-78 and L-428, respectively. Figure 
4.3 shows the ∆Ct values after normalization with the housekeeping gene, GAPDH, to correct 
for differences in the amount of cDNA added to each reaction. There was an 8 cycle 
difference between Karpas-422 and healthy lymphocytes and thus MCT4 was expressed 256 
times higher in Karpas-422 than in healthy lymphocytes. In Raji and SUDHL-4, the 
expression of MCT4 was slightly downregulated, with the healthy samples expressing more 
MCT4. In Jurkat and HUT-78, the expression was 64 times that in healthy lymphocytes. The 
cycle difference between L-428 and healthy lymphocytes was around 10, indicating a very 
high expression of MCT4 in this cell line.  




































































 Fig 4.3  TaqMan real-time PCR analysis for MCT4 expression in total RNA  
 extracted from six lymphoma cell lines. MCT4 expression was normalized   
 using GAPDH. Expression in healthy samples obtained from the blood bank was  
 set to 0.  
 
Seven CLL patient samples were analyzed for MCT4 expression (Figure 4.4). In general, 
MCT4 expression was downregulated in all samples tested. While in the healthy lymphocytes, 
MCT4 was expressed at cycle 35, in the patient samples tested, MCT4 expression was 




between cycles 32- 37. After normalization with GAPDH, there was a 256 times higher 
expression of MCT4 in healthy lymphocytes than in CLL patient samples. One patient 
sample, CLL11, did not express MCT4.  








































































 Fig 4.4  TaqMan real-time PCR analysis for MCT4 expression in total RNA  
 extracted from peripheral blood from CLL patients. MCT4 expression was   
 normalized using GAPDH. Expression in healthy samples obtained from the blood  
 bank was set to 0. X denotes no expression of MCT4 in CLL11. 
 
4.1.2.3 Expression of SLC19 family transporters 
The folate transporter, RFT (SLC19A1), was expressed in all cell lines tested (Figure 4.5). 
The expression was the strongest in L-428. The healthy lymphocytes exhibited a relatively 
lower expression than the cell lines. 
 Thiamine transporter ThTr1 (SLC19A2) was expressed in all cell lines. However, SUDHL-4 
showed a very low expression of ThTr1, while the other five cell lines exhibited a high 
expression. The expression level in healthy lymphocytes was seemingly lower than the five 
cell lines.  














 Fig 4.5  RT-PCR screening of SLC19 family transporters in lymphoma cell lines. K: 
 Karpas-422, R: Raji, S: SUDHL-4, J: Jurkat, H: HUT-78, L: L-428, HP-1: Healthy person 
 sample-1, HP-2: Healthy person sample- 2, +: positive control, -: negative control.  
 
4.1.2.4 Expression of SLCO (SLC 21) family transporters 
SLCO transporters were differentially expressed in the lymphoma cell lines, as shown in 
Figure 4.6. OATP-B (OATP2B1) was expressed in only two B- lymphoma cell lines, 
SUDHL-4 and L-428. Healthy lymphocytes did not express OATP-B.  
OATP-D (OATP3A1) was expressed in five cell lines. The expression was the strongest in 
Jurkat. Raji had a comparatively lower expression of OATP-D. Karpas-422 did not express 
OATP-D while the expression of the gene in the healthy lymphocytes was very low. 
OATP-E (OATP4A1) was expressed in all six cell lines tested. Karpas-422, SUDHL-4, Jurkat 
and L-428 exhibited comparable levels of expression while HUT-78 exhibited the highest 
expression of OATP-E. OATP-E expression in Raji was stronger than observed in other B-




K R      S     J      H      L     +    HP-1  -
 
 








           
OATP-E
193 bp
K    R     S       J      H       L      HP-1  +             -
 
 Fig 4.6  RT-PCR screening of SLCO (SLC21) family transporters in lymphoma cell 
 lines. K: Karpas-422, R: Raji, S: SUDHL-4, J: Jurkat, H: HUT-78, L: L-428, HP-1: 
 Healthy person sample-1, +: positive control, -: negative control.  
For real-time PCR analysis, we quantified the expression of OATP-B (OATP2B1) and 
OATP-E (OATP4A1).  
OATP-B was expressed at high levels in three B- lymphoma cell lines, Karpas-422, Raji and 
L-428 (Figure 4.7). While the expression of OATP-B was observed between cycles 25-28 in 
the three cell lines, there was no expression of OATP-B in healthy lymphocytes even after 40 
cycles. The figure shows OATP-B expression in lymphoma cell lines after normalization with 
GAPDH.  The gene was not expressed in SUDHL-4, Jurkat and HUT-78 after 40 cycles.  
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 Fig 4.7 TaqMan real-time PCR analysis for OATP-B expression in total RNA extracted 
 from six lymphoma cell lines. OATP-B expression was normalized using GAPDH. No 
 expression of OATP-B was seen in healthy samples. X denotes no expression of OATP-B in 
 the four cell lines. 
 




OATP-E expression was also examined in the six lymphoma cell lines (Figure 4.8). Jurkat 
showed the strongest expression of the gene with the expression observed at cycle 25. After 
normalization, Jurkat expressed OATP-E 65000 times higher than healthy lymphocytes, 
where the gene expression was observed at cycle 34. Karpas-422 and Raji also exhibited more 
than 4000 times higher OATP-E expression than healthy lymphocytes. The expression of the 
gene in SUDHL-4, HUT-78 and L-428 was also calculated to be more than 16 times that in 
healthy lymphocytes. In the cell lines tested, SUDHL-4 showed the lowest expression.  





































































 Fig 4.8 TaqMan real-time PCR analysis for OATP-E expression in total RNA extracted 
 from six lymphoma cell lines. OATP-E expression was normalized using GAPDH. 
 Expression in healthy samples obtained from the blood bank was set to 0.  
 
The seven patient samples tested for OATP-B did not show any observable gene expression. 
The same set of patient samples was also tested for OATP-E expression (Figure 4.9). While 
OATP-E was observed at cycle 29 in healthy samples, it appeared between cycles 32 and 37 
in the patient samples.  Four of the seven patients samples tested exhibited 16 to 256 times 
lower expression of OATP-E than healthy lymphocytes. Patient samples CLL11 and CLL16 




did not express OATP-E after 40 cycles. Patient sample CLL12 showed a slightly higher 











































































 Fig 4.9 TaqMan real-time PCR analysis for OATP-E expression in total RNA extracted 
 from peripheral blood from CLL patients. OATP-E expression was normalized using 
 GAPDH. Expression in healthy samples obtained from the blood bank was set to 0. X denotes 
 no expression of OATP-E in CLL11 and CLL16.  
 
4.1.2.5 Expression of SLC22 family transporters 
OCT1 (SLC22A1) was expressed in the six lymphoma cell lines we tested (Figure 4.10). 
Karpas-422, SUDHL-4 and Jurkat had a seemingly higher expression of the gene. Healthy 
lymphocytes demonstrated a much lower expression of OCT1 than the cell lines.  
Organic anion transporter 1, OAT1 (SLC22A6) was also expressed in all six cell lines, The 
expression was the strongest for Karpas-422. The expression in Jurkat, HUT-78 and L-428 
was comparable to that in healthy lymphocytes.  
 













 Fig 4.10  RT-PCR screening of SLC22 family transporters in lymphoma cell lines. Of the 
 organic cation transporters tested, only OCT1 (SLC22A1) demonstrated expression in the cell 
 lines. OAT1 (SLC22A6) was the only organic anion transporter expressed. K: Karpas-422, R: 
 Raji, S: SUDHL-4, J: Jurkat, H: HUT-78, L: L-428, HP-1: Healthy person sample-1, +: 
 positive control, -: negative control.  
 
Real-time PCR analysis of OCT1 revealed a higher expression of the gene in five cell lines 
when compared to healthy lymphocytes (Figure 4.11). The gene was expressed at cycle 35 in 
healthy lymphocytes while in the cell lines it was expressed at cycles 34-36. SUDHL-4 
showed a particularly low expression of the gene and the expression, after normalization, was 
found to be 256 times lower than in healthy lymphocytes. The other five cell lines 








































































 Fig 4.11 TaqMan real-time PCR analysis for OCT1 expression in total RNA extracted 
 from six lymphoma cell lines. OCT1 expression was normalized using GAPDH. Expression 
 in healthy samples obtained from the blood bank was set to 0.  




OCT6 was also tested for expression in lymphoma cell lines using real-time PCR (Figure 
4.12). The healthy lymphocytes expressed the gene at cycle 33. No expression for OCT6 was 
seen after 40 cycles in Karpas-422, Raji, SUDHL-4 and Jurkat. In HUT-78 and L-428, OCT6 
was expressed at cycles 34 and 36, respectively. Normalization resulted in a cycle difference 
of 1.5 between the gene expression in the cell lines and healthy lymphocytes, with the two 
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 Fig 4.12 TaqMan real-time PCR analysis for OCT6 expression in total RNA extracted 
 from six lymphoma cell lines. OCT6 expression was normalized using GAPDH. Expression 
 in healthy samples obtained from the blood bank was set to 0. X denotes no expression of 
 OCT6 in the four cell lines. 
 
In CLL patient samples, OCT1 expression was expressed at higher levels than in healthy 
lymphocytes (Figure 4.13). In the healthy lymphocytes, OCT1 was seen at cycle 31 while in 
the patient samples, expression of OCT1 was seen between cycles 29 and 35. Normalization 
gave a mean cycle difference of 2 between the seven CLL patient samples and the healthy 
lymphocytes, with the patient samples exhibiting higher OCT1 expression.  




































































 Fig 4.13 TaqMan real-time PCR analysis for OCT1 expression in total RNA extracted 
 from peripheral blood from CLL patients. OCT1 expression was normalized using 
 GAPDH. Expression in healthy samples obtained from the blood bank was set to 0.  
 
OCT6 expression in CLL patient samples was found to be higher than in healthy lymphocytes (Figure 
4.14). In one experiment, OCT6 was expressed at cycle 37 in healthy lymphocytes while in the patient 
samples this number ranged between 34 and 37. Patient sample CLL7 exhibited a lower expression of 
OCT6 than healthy lymphocytes.  
   





































































 Fig 4.14 TaqMan real-time PCR analysis for OCT6 expression in total RNA extracted 
 from peripheral blood from CLL patients. OCT6 expression was normalized using 
 GAPDH. Expression in healthy samples obtained from the blood bank was set to 0.  
 
Real-time PCR analysis for OAT1 expression in the lymphoma cell lines revealed a higher 
expression than healthy lymphocytes (Figure 4.15). In the lymphoma cell lines, OAT1 was 
quantifiable at cycle 32, while this cycle number was 33 in healthy lymphocytes. 
Normalization with GAPDH revealed at least a four times higher expression in lymphoma cell 
lines than healthy lymphocytes. The exception was HUT-78 where OAT1 expression was 
only slightly higher than in healthy lymphocytes.  




































































 Fig 4.15 TaqMan real-time PCR analysis for OAT1 expression in total RNA extracted 
 from six lymphoma cell lines. OAT1 expression was normalized using GAPDH. Expression 
 in healthy samples obtained from the blood bank was set to 0.  
 
While RT-PCR analysis did not reveal OAT2 expression in the six lymphoma cell lines we tested, 
OAT2 expression was seen in these cell lines using real-time PCR analysis. Figure 4.16 below shows 
the mean expression from three different experiments with two replicates each. OAT2 was expressed 
at cycles 27-32 in the lymphoma cell lines. In healthy lymphocytes, OAT2 expression was seen at 
cycle 32. Normalization was done with GAPDH and OAT2 expression was seen to be higher in 
lymphoma cell lines than the control, healthy lymphocytes. The highest expression was seen for 
SUDHL-4 where the expression was nearly 64 times higher than healthy lymphocytes. The other five 
cell lines showed 8 to 32 times higher expression of the gene compared to healthy lymphocytes.  





































































 Fig 4.16 TaqMan real-time PCR analysis for OAT2 expression in total RNA extracted 
 from six lymphoma cell lines. OAT2 expression was normalized using GAPDH. Expression 
 in healthy samples obtained from the blood bank was set to 0.  
 
Only OAT1 expression was seen in the seven patient samples tested for organic anion 
transporter expression (Figure 4.17). While in the healthy lymphocytes OAT1 was 
quantifiable at cycle 32, the CLL patient samples showed typical cycle values of 35-37. 
Following normalization with GAPDH, OAT1 expression in CLL patient samples was found 
to be much lower than that in healthy lymphocytes. A mean ∆Ct of -6 was calculated for the 
CLL patient samples, indicating 64 times lower expression of OAT1 in these samples than in 
healthy lymphocytes.  
















































































 Fig 4.17 TaqMan real-time PCR analysis for OAT1 expression in total RNA extracted 
 from peripheral blood from CLL patients. OAT1 expression was normalized using 
 GAPDH. Expression in healthy samples obtained from the blood bank was set to 0.  
 
4.1.2.6 Expression of SLC29 family transporters 
RT-PCR analysis for ENT1 revealed a high expression in all the cell lines tested (Figure 
4.18). The healthy lymphocytes showed a slightly lower expression of the gene.  
ENT2 expression in the cell lines was much lower. Raji, HUT-78 and L-428 showed similar 
expression levels and this was comparable to the expression of ENT2 in healthy lymphocytes. 
Karpas-422 had a lower expression. The lowest expression was seen in Jurkat while SUDHL-
4 did not express ENT2 at all. 
ENT3 was expressed in all the six lymphoma cell lines tested. Karpas-422 showed a lower 
expression of the gene while the other five cell lines as well as the healthy lymphocytes’ 
samples had comparable ENT3 expression.  
  

















K      R    S       J        H        L       HP-1  HP-2  +         -
 
 Fig 4.18 RT-PCR screening of SLC29 family transporters in lymphoma cell lines with all 
 three transporters tested being expressed in the six cell lines. K: Karpas-422, R: Raji, S: 
 SUDHL-4, J: Jurkat, H: HUT-78, L: L-428, HP-1: Healthy person sample-1, HP-2: Healthy 
 person sample- 2, +: positive control, -: negative control.  
 
Consistent with RT-PCR results, ENT1 was expressed at higher levels than normal in five cell 
lines, with the exception of the T-lymphoma cell line, Jurkat which exhibited a lower ENT1 
expression (Figure 4.19). ENT1 was typically expressed between cycles 26-28 in the 
lymphoma cell lines while in healthy lymphocytes, it was expressed at cycle 32. For Jurkat, 
this cycle number was 35. Normalization with GAPDH was done and a mean ∆Ct of 5 was 
calculated for the five cell lines. In Jurkat, ENT1 expression was nearly 16 times lower than 
in healthy lymphocytes.  









































































 Fig 4.19 TaqMan real-time PCR analysis for ENT1 expression in total RNA extracted 
 from six lymphoma cell lines. ENT1 expression was normalized using GAPDH. Expression 
 in healthy samples obtained from the blood bank was set to 0.  
 
ENT2 was expressed at very high levels in five of the six cell lines tested (Figure 4.20). Consistent 
with the RT-PCR data, no expression of ENT2 was seen in SUDHL-4. In the other five lymphoma cell 
lines, ENT2 was typically expressed between cycles 26-30. In healthy lymphocytes, ENT2 was 
expressed at cycle 33. Normalization with GAPDH revealed more than 16 times higher expression in 
the lymphoma cell lines than healthy lymphocytes. Raji demonstrated the highest ENT2 expression, 
with nearly 128 times higher expression of the gene compared to the control, healthy lymphocytes.  






































































 Fig 4.20 TaqMan real-time PCR analysis for ENT2 expression in total RNA extracted 
 from six lymphoma cell lines. ENT2 expression was normalized using GAPDH. Expression 
 in healthy samples obtained from the blood bank was set to 0. X denotes no expression of 
 ENT2 in SUDHL-4. 
 
ENT3 was also seen to be expressed higher in the lymphoma cell lines than in healthy lymphocytes 
(Figure 4.21). While no expression of ENT3 was seen in SUDHL-4, the five cell lines showed 
expression at cycles 28-30. The healthy lymphocytes showed an expression of ENT3 at cycle 32. After 
normalization ENT3 was seen to be typically expressed 16 to 64 times higher in five lymphoma cell 
lines than in healthy lymphocytes. The highest expression was seen in Raji.  





































































 Fig 4.21 TaqMan real-time PCR analysis for ENT3 expression in total RNA extracted 
 from six lymphoma cell lines. ENT3 expression was normalized using GAPDH. Expression 
 in healthy samples obtained from the blood bank was set to 0. X denotes no expression of 
 ENT3 in SUDHL-4. 
 
ENT1 expression in seven CLL patient samples was analyzed using real-time PCR (Figure 
4.22). One patient sample, CLL26, did not show ENT1 expression even after 40 cycles. In the 
other patient samples tested, ENT1 appeared at cycles 31-37, in healthy lymphocytes at cycle 
26. ENT1 was typically expressed 64 times lower in patient samples compared to healthy 
lymphocytes.  













































































 Fig 4.22 TaqMan real-time PCR analysis for ENT1 expression in total RNA extracted 
 from peripheral blood from CLL patients. ENT1 expression was normalized using 
 GAPDH. Expression in healthy samples obtained from the blood bank was set to 0. X denotes 
 no expression of ENT1 in CLL26. 
 
ENT2 expression was also much lower in CLL patient samples than in healthy lymphocytes (Figure 
4.23). CLL26 did not show ENT2 expression at all while in the other six patient samples, a mean ∆Ct 
of -9 was calculated, indicating a much lower expression of the gene in these samples. In the healthy 
lymphocytes, ENT2 expression was seen at cycle 34 while this number was between 35-38 in patient 
samples.  













































































 Fig 4.23 TaqMan real-time PCR analysis for ENT2 expression in total RNA extracted 
 from peripheral blood from CLL patients. ENT2 expression was normalized using 
 GAPDH. Expression in healthy samples obtained from the blood bank was set to 0. X denotes 
 no expression of ENT2 in CLL26. 
 
ENT3 expression was not seen in patient sample CLL26 (Figure 4.24). The other patient 
samples tested gave a mean ∆Ct value of -7, indicating a nearly 128 times lower expression of 
ENT3 in CLL patient samples than in healthy lymphocytes. In healthy lymphocytes, ENT3 
expression was seen at cycle 34 while in CLL patient samples, this number ranged within 31-
38.  













































































 Fig 4.24 TaqMan real-time PCR analysis for ENT3 expression in total RNA extracted 
 from peripheral blood from CLL patients. ENT3 expression was normalized using 
 GAPDH. Expression in healthy samples obtained from the blood bank was set to 0. X denotes 
 no expression of ENT3 in CLL26. 
 
4.1.3 Expression of ABC transporters 
All investigated members of the ABC family were expressed in the lymphoma cell lines 
(Figure 4.25). MDR1 was expressed at the highest levels. Only one B-lymphoma cell line, 
SUDHL-4 did not express MDR1. HUT-78 and L-428 had nearly comparable expression to 
that in normal lymphocytes. The expression was slightly lower in Karpas-422 and Raji and 
still lower in Jurkat.  
 MRP1 was consistently expressed in lymphoma cell lines. Strongest expression of MRP1 
was observed in HUT-78 and L-428 and this was again comparable to MRP1 expression in 
healthy lymphocytes. SUDHL-4 demonstrated a much lower expression of MRP1 than the 
other cell lines tested. Karpas-422, Raji and Jurkat had comparable expression of the gene.  
MRP2 showed a high expression in L-428. Karpas-422 and Jurkat had comparable expression 
of the gene while HUT-78 demonstrated a relatively lower expression. Raji, SUDHL-4 and 
the healthy lymphocytes did not show MRP2 expression. 




MRP4 was expressed at very low levels in the cell lines. While Raji and SUDHL-4 
demonstrated negligible gene expression, the expression of MRP4 in Karpas-422, Jurkat and 
HUT-78 was nearly comparable to that in healthy lymphocytes. L-428 showed a slightly 
stronger expression of MRP4 than healthy lymphocytes. 
 



















 Fig 4.25 RT-PCR screening of ABC transporters in lymphoma cell lines K: Karpas-422, 
 R: Raji, S: SUDHL-4, J: Jurkat, H: HUT-78, L: L-428, HP-1: Healthy person sample-1, HP-2: 
 Healthy person sample- 2, +: positive control, -: negative control.  
 
4.2 OCT1 and OCT2 mediated MPP uptake in cells 
MPP+, 1-methyl-4-phenylpyridinium, is a known substrate of Organic Cation Transporters 
(31). To ensure that our cells expressed functional proteins, we measured radiolabelled MPP 
uptake in CHO cells, stably expressing OCT1 and OCT2 (Figure 4.26). The uptake of 20 nM 
[3H]MPP in CHO-OCT1 was 123.8 ± 0.41 fmol/5 min, which was 14 fold higher than CHO 
control cells (8.45 ± 0.86 fmol/5 min, P<0.0001). OCT1 mediated [3H]MPP uptake was 
significantly inhibited by 50 µM unlabelled (cold) MPP (25.38 ± 0.50%, P<0.0001) and 100 
µM unlabelled MPP (20.64 ± 0.44%, P<0.0001). OCT2 mediated [3H]MPP was  60.25 ± 2.57 
fmol/5 min and this was again significantly inhibited by 50 µM unlabelled MPP (21.08 ± 
1.56%, P< 0.0001)  and 100 µM unlabelled MPP (17.88 ± 0.47%, P< 0.0001). The addition of 




500 µM unlabeled MPP resulted in complete abolishment of [3H]MPP uptake by both OCT1 

















































 Fig 4.26 Inhibition of [
3
H]MPP uptake into OCT1 and OCT2 cells. Cells were incubated 
 with 20 nM [3H]MPP alone or in addition with 50 µM, 100 µM and 500 µM unlabelled MPP 
 for 5 minutes. Data are means of three independent experiments with four repeats each. 
 ***P< 0.0001 
 
 4.2.1 Cis-Inhibition of OCT1 and OCT2 mediated MPP uptake by cytostatics 
The interaction of cytostatics with OCT1 and OCT2 was determined by inhibition of 
[3H]MPP uptake by these cells. Several groups of cytostatics were tested for their interaction 
with OCT1 and OCT2, and thus the inhibition of OCT-mediated MPP uptake.  
4.2.1.1  Cis-Inhibition of OCT1 and OCT2 mediated MPP uptake by alkylating drugs 
We tested 7 alkylating drugs for their interaction with OCT1 and OCT2. Ifosphamide and 
trofosphamide significantly reduced MPP uptake by OCT1 to 71.45 ± 4.37%, P< 0.0001 and 
55.74 ± 6.34%, P< 0.0001, respectively (Figure 4.27). Bendamustine also effected OCT1 
mediated MPP uptake and reduced it to 75.84 ± 9.24% (P< 0.05). The inhibition of MPP 
uptake by OCT1 was reduced to 76.72 ± 18.32% by melphalan. Cyclophosphamide, 
treosulfan and chlorambucil stimulated MPP uptake by OCT1 to 111.47 ± 7.79%, 101.07 ± 
5.74% and 110.18 ± 5.45%, respectively. This increased MPP uptake, however, was not 




significant. Treosulfan also resulted in a slightly increased MPP uptake by the control cells 







































































































 Fig 4.27 Inhibition of [
3
H]MPP uptake by alkylating agents (100 µM each) in CHO-
 OCT1 cells. The control set (without inhibitor) was set at 100 %. Data are means of three 
 independent experiments with four repeats each. * P< 0.05, **P< 0.01 
 
MPP uptake by OCT2 was significantly inhibited by ifosphamide, cyclophosphamide, 
busulfan and bendamustine to 51.21 ± 7.74%, P< 0.0001; 71.68 ± 9.23%, P< 0.05; 49.10 ± 
6.60%, P< 0.0001 and 54.13 ± 10.59%, P< 0.001, respectively (Figure 4.28). Treosulfan and 
chlorambucil also inhibited OCT2 mediated MPP uptake and reduced it to 83.84 ± 10.75% 
and 77.70 ± 12.68%, respectively. This observed inhibition was not significant. 
Trofosphamide and melphalan did not affect OCT2 mediated MPP uptake.   













































































































 Fig 4.28 Inhibition of [
3
H]MPP uptake by alkylating agents (100 µM each) in CHO-
 OCT2 cells. The control set (without inhibitor) was set at 100 %. Data are means of three 
 independent experiments with four repeats each. * P< 0.05, **P< 0.01 
 
4.2.1.2 Cis-Inhibition of OCT1 and OCT2 mediated MPP uptake by antimetabolites 
None of the antimetabolites tested inhibited MPP uptake by OCT1 (Figure 4.29). However, 
the sugar analog, cytosine arabinoside did result in a stimulation of MPP uptake to 145.10 ± 
13.83%, P< 0.001. Cladribine also resulted in a slightly increased MPP uptake by OCT1 cells 
to 109.66 ± 6.04%, but this change was not significant. The control cells showed a non- 
significant increase in MPP uptake on treatment with antimetabolites, particularly on 
treatment with cytosine arabinoside and gemcitabine.  


























































































 Fig 4.29 Inhibition of [3H]MPP uptake by antimetabolites (100 µM each) in CHO-OCT1 
 cells. The control set (without inhibitor) was set at 100 %. Data are means of three 
 independent experiments with four repeats each. **P< 0.01 
 
OCT2 mediated MPP uptake was non-significantly inhibited by fluoroadenine and 
fludarabine to 85.98 ± 4.51% and 86.72 ± 15.97%, respectively  (Figure 4.30). Methotrexate, 
cytosine arabinoside and cladribine did not affect MPP uptake by OCT2. Gemcitabine, 
however, increased MPP uptake in OCT2 cells to 114.17 ± 13.46 and in control cells to 14.81 
± 2.56%. However, the increase observed in both the cells lines was not significant. 






















































































 Fig 4.30 Inhibition of [
3
H]MPP uptake by antimetabolites (100 µM each) in CHO-OCT2 
 cells. The control set (without inhibitor) was set at 100 %. Data are means of three 
 independent experiments with four repeats each.  
 
4.2.1.3 Cis-Inhibition of OCT1 and OCT2 mediated MPP uptake by topoisomerase 
inhibitors 
Two of the three topoisomerase inhibitors tested, mitoxantrone and irinotecan, dramatically 
reduced [3H]MPP uptake by OCT1 cells, inhibiting the uptake to 25.42 ± 2.01% (P< 0.0001)  
and 16.65 ± 1.88% (P< 0.0001), respectively (Figure 4.31). Etoposide also inhibited MPP 
uptake by OCT1 to 79.33 ± 5.59%, but this inhibition was not significant. Control cells 
demonstrated a higher MPP uptake than normal on irinotecan treatment to 15.17 ± 1.75%. 
This increased uptake by the control cells was not significant.   




























































 Fig 4.31 Inhibition of [
3
H]MPP uptake by topoisomerase inhibitors (100 µM each) in 
 CHO-OCT1 cells. The control set (without inhibitor) was set at 100 %. Data are means of 
 three independent experiments with four repeats each. ***P< 0.0001 
 
Since the OCT1 mediated MPP uptake was strongly inhibited by mitoxantrone and irinotecan, 
we measured the affinity of OCT1 for these two cytostatics.  We performed apparent Km (Ki) 
analysis. 
Three experiments were performed for the kinetic analysis of OCT1 for mitoxantrone. 
Increasing concentrations of mitoxantrone (0-140 µM) were used with 1 µM and 20 µM 
[3H]MPP for the assay. A representative example is shown below (Figure 4.32) and the Ki 
was determined to be 85.2 µM. 
 




                  
Ki = 85.2 µM
Mitoxantrone [µM] 

























 Fig 4.32 Dixon plot studies on OCT1 expressing CHO cells showing an interaction of 
 mitoxantrone with OCT1 giving a Ki of 85.2µM. Uptake experiments were carried out with 
 ● 1µM and ○ 20µM MPP with different concentrations of mitoxantrone. A representative 
 experiment is shown. Data are means ±SEM of three data repeats. 
 
For the determination of irinotecan kinetics, OCT1 was assayed for 1 µM [3H]MPP uptake 
and 20 µM [3H]MPP uptake over 5 minutes in the presence of increasing concentrations of 
unlabelled irinotecan (0-20 µM). Figure 4.33 shows a representative example of Dixon plot 
analysis in OCT1 and in this experiment, the Ki was determined to be 1.73 µM.   




                    
Ki = 1.71µM
Irinotecan [µM] 























 Fig 4.33 Dixon plot studies on OCT1 expressing CHO cells showing an interaction of 
 irinotecan with OCT1 giving a Ki of 1.73 µM. Uptake experiments were carried out with 
 ● 1µM and ○ 20µM MPP with different concentrations of irinotecan. A representative 
 experiment is shown. Data are means ±SEM of three data repeats. 
 
Mitoxantrone and irinotecan effected a reduced MPP uptake by OCT2 cells to 58.72 ± 
14.96%, P< 0.05 and 28.51 ± 3.30%, P< 0.0001, respectively (Figure 4.34). Etoposide also 
inhibited MPP uptake by OCT2 to 70.07 ± 4.87%, but this inhibition was not significant.  


























































 Fig 4.34 Inhibition of [
3
H]MPP uptake by topoisomerase inhibitors (100 µM each) in 
 CHO-OCT2 cells. The control set (without inhibitor) was set at 100 %. Data are means of 
 three independent experiments with four repeats each. * P< 0.05, ***P< 0.0001 
 
We looked for the affinity of OCT2 for irinotecan using an indirect method for calculating the 
apparent Km value. Three separate experiments were made using increasing concentrations of 
unlabelled irinotecan (0-20 µM). 1 µM [3H]MPP uptake and 20 µM [3H]MPP uptake over 5 
minutes was measured and the Ki value for irinotecan was calculated to be 86.3 µM. Figure 
4.35 gives a representative example of Dixon plot studies on OCT2 for irinotecan.  
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 Fig 4.35 Dixon plot studies on OCT2 expressing CHO cells showing an interaction of 
 irinotecan with OCT2 giving a Ki of 86.3 µM. Uptake experiments were carried out with 
 ● 1µM and ○ 20µM MPP with different concentrations of irinotecan. A representative 
 experiment is shown. Data are means ±SEM of three data repeats. 
 
4.2.1.4 Cis- Inhibition of OCT1 and OCT2 mediated MPP uptake by cytostatics acting on 
mitotic spindle 
Paclitaxel and vinblastine significantly inhibited OCT1 mediated [3H]MPP uptake and 
reduced it to 28.54 ± 5.31%, P< 0.0001 and 55.42 ± 9.63%, P< 0.0001, respectively (Figure 
4.36). Vincristine did not affect MPP uptake by OCT1. The control cells exhibited an 
increased MPP uptake on treatment with vincristine and vinblastine to 14.93 ± 1.56% and 
16.36 ± 2.33%, respectively. This increase, however, was non-significant.  
 

























































 Fig 4.36 Inhibition of [
3
H]MPP uptake by cytostatic agents acting on mitotic spindle (100 
 µM each) in CHO-OCT1 cells. The control set (without inhibitor) was set at 100 %. Data are 
 means of three independent experiments with four repeats each. **P< 0.01 
 
Dixon plot analysis was done to determine the affinity of OCT1 for paclitaxel. OCT1 was 
assayed for 1 µM and 20 µM [3H]MPP uptake over 5 minutes in the presence increasing 
concentrations of paclitaxel (0- 140 µM). The Ki was calculated to be 50.1 µM from the 
representative experiment shown in Figure 4.37.  
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 Fig 4.37 Dixon plot studies on OCT1 expressing CHO cells showing an interaction of 
 paclitaxel with OCT1 giving a Ki of 50.1µM. Uptake experiments were carried out with ● 
 1µM and ○ 20µM MPP with different concentrations of paclitaxel. A representative 
 experiment is shown. Data are means ±SEM of three data repeats. 
 
 
OCT2 mediated MPP uptake was significantly inhibited by paclitaxel to 51.23 ± 8.13%, P< 
0.001 (Figure 4.38). Vincristine did not affect MPP uptake by OCT2 but vinblastine resulted 
in an increased OCT2 mediated MPP uptake to 118.88 ± 15.73%. This increased MPP uptake 
in the presence of vinblastine was non- significant.  
 

























































 Fig 4.38 Inhibition of [
3
H]MPP uptake by cytostatic agents acting on mitotic spindle (100 
 µM each) in CHO-OCT2 cells. The control set (without inhibitor) was set at 100 %. Data are 
 means of three independent experiments with four repeats each. **P< 0.01 
 
4.2.1.5  Cis-Inhibition of OCT1 and OCT2 mediated MPP uptake by cytostatics acting on 
steroid hormone receptors 
Prednisone inhibited OCT1 mediated [3H]MPP uptake to 74.71 ± 4.14% (P< 0.001) while 
clodronic acid resulted in slight stimulation of [3H]MPP uptake (111.97 ± 3.96%, P< 0.05), as 
shown in Figure 4.39.  





















































 Fig 4.39 Inhibition of [
3
H]MPP uptake by drugs acting on steroid hormone receptors 
 (100 µM each) in CHO-OCT1 cells. The control set (without inhibitor) was set at 100 %. 
 Data are means of three independent experiments with four repeats each. * P< 0.05 
 
OCT2 mediated [3H]MPP uptake was also significantly inhibited by 100 µM prednisone 
(65.85 ± 9.01%, P< 0.001). Clodronic acid did not affect MPP uptake by OCT2 cells (Figure 
4.40).  



















































 Fig 4.40 Inhibition of [
3
H]MPP uptake by drugs acting on steroid hormone receptors 
 (100 µM each) in CHO-hOCT2 cells. The control set (without inhibitor) was set at 100 %. 
 Data are means of three independent experiments with four repeats each. **P< 0.01 
 
4.3 Transporter mediated transporter sensitivity 
For elucidating the role of OCT1 and OCT2 in the uptake of cytostatics and their resultant 
cytotoxicity, we performed MTT assays in stably transfected CHO cells expressing OCT1 and 
OCT2, as well as in two B-lymphoma cell lines: L-428, with high OCT1 expression, and 
SUDHL-4, with no OCT1 expression. Cells were treated with the cytostatic alone and 
together with TEA, a known substrate of OCTs and corticosterone, an inhibitor of OCTs. An 
incubation time of only 15 minutes was used to ensure that the effects observed were 
transporter mediated and not due to any other factors (like passive diffusion). 
4.3.1 Evaluation of OCT1 and OCT2 mediated cytotoxicity of irinotecan using the MTT 
assay 
Figure 4.41 demonstrates the cell viability assay performed in OCT1 and OCT2 expressing 
CHO cells on treatment with irinotecan. Irinotecan, which specifically interacts with OCT1 




and OCT2, resulted in a decrease in cell viability after 15 minutes of cytostatic treatment. The 
decrease in cell viability was 30 ± 4.5%, P <0.05; and 23 ± 3.3%, P< 0.001, in OCT1 and 
OCT2 cells, respectively. Treatment with TEA and corticosterone alone did not affect OCT2. 
In OCT1 cells, however, incubation with TEA and corticosterone increased cell viability to 
112.33 ± 8.84% and 112.45 ± 7.66%, respectively. The observed increase in cell viability was 
not significant. Treatment of OCT1 and OCT2 cells with irinotecan and TEA simultaneously, 
demonstrated a reversal in reduced cell viability seen with irinotecan alone with no observable 
differences from that of the control set (104.27 ± 10.71% and 99.71 ± 1.98%, respectively). 
Similar results were obtained on simultaneous treatment of cells with irinotecan and 
corticosterone, with cell viability comparable to that of the control conditions. OCT1 
expressing cells exhibited a cell viability of 113.77 ± 6.44% and OCT2 cells 100.57 ± 0.45%. 
Mock cells (non- transfected CHO-K1 cells) did not exhibit changes in cell viability under the 
















































































 Fig 4.41 OCT1 and OCT2 mediated cytotoxicity of irinotecan was determined using the 
 MTT assay. Cells were treated with 100 µM Irinotecan for 15 min, washed with PBS and 
 incubated in cell culture medium for an additional 24 h at 37 °C. Irinotecan toxicity on CHO-
 OCT1 and CHO-OCT2 was reversed by the addition of TEA and corticosterone. Data are 
 means of three independent experiments with four repeats each. *P<0.05, **P< 0.01 
 




The MTT assay for irinotecan on B-lymphoma cell lines is shown in Figure 4.42. L-428 
demonstrated a decrease in cell viability by 15.7 ± 1.84% (P< 0.0001) on irinotecan treatment 
alone. On treatment of cells with irinotecan and TEA simultaneously, L-428 cells showed a 
very slight reversal in decreased cell viability to 14 ± 2.45% (P< 0.0001). When 
corticosterone and irinotecan were applied to cells simultaneously, L-428 cells demonstrated a 
decrease of only 12.91 ± 2.88% (P< 0.001). SUDHL-4, not expressing OCT1 or OCT2, 



















































































 Fig 4.42 OCT1 mediated cytotoxicity of irinotecan was determined using the MTT assay 
 in the B- lymphoma cell line, L-428. SUDHL-4, with no observed expression of OCT1, was 
 used as a control. Cells were treated with 100 µM irinotecan for 15 min, washed with PBS and 
 incubated in cell culture medium for an additional 24 h at 37 °C. Data are means of three 
 independent experiments with four repeats each. **P<0.01, ***P< 0.0001 
 
4.3.2 Evaluation of OCT1 mediated cytotoxicity of mitoxantrone using the MTT assay 
The effect of the topoisomerase inhibitor mitoxantrone on cell viability was examined in 
OCT1 expressing cells (Figure 4.43). Cells were treated with 100 µM mitoxantrone alone and 
together with 2 mM TEA and 100 µM corticosterone. On mitoxantrone treatment alone, 
OCT1 expressing cells exhibited reduced cell viability by 40.8 ± 2.54%, P< 0.001. Mock cells 




also demonstrated decreased cell viability by 8.44 ± 7.8 % although this was not significant. 
On treatment with mitoxantrone and TEA together, cell viability was reduced by only 3.2 ± 
2.6% and this change from mitoxantrone cytotoxicity was significant. Mitoxantrone and 
corticosterone treatment of cells resulted in a significant reversal of the decrease in cell 

























































































 Fig 4.43 OCT1 mediated cytotoxicity of mitoxantrone was determined using the MTT 
 colorimetric assay. Cytotoxicity of mitoxantrone was tested by incubating the cells with 100 
 µM cytostatic for 15 min, followed by washing with PBS and an overnight incubation in cell 
 culture medium at 37 °C. Data are means of three independent experiments with four repeats 
 each. **P< 0.01 
 
The decrease in cell viability observed in the two B-lymphoma cell lines was more dramatic, 
with mitoxantrone treatment alone effecting a decrease in cell viability by 45.87 ± 2.69%, P< 
0.0001 and 65.45 ± 3.49%, P< 0.0001 in L-428 and SUDHL-4 cells, respectively (Figure 
4.44). The observed decrease in cell viability in both cell lines could not be reversed on 
simultaneous treatment with TEA and corticosterone. On simultaneous application of 
mitoxantrone and TEA, the cell viability decreased to 54.87 ± 3.74%, P< 0.0001 in L-428 and 
to 33.04 ± 3.17%, P< 0.0001 in SUDHL-4. The decrease in cell viability observed on 




treatment with mitoxantrone and corticosterone was 55.46 ± 3.93%, P< 0.0001 and 26.95 ± 







































































































 Fig 4.44 OCT1 mediated cytotoxicity of mitoxantrone was examined using the MTT 
 assay in the B- lymphoma cell lines, L-428 and SUDHL-4. Cells were treated with 100 µM 
 mitoxantrone for 15 min, washed with PBS and incubated in cell culture medium for an 
 additional 24 h at 37 °C. Mitoxantrone cytotoxicity was not reversed on simultaneous 
 incubation with TEA and corticosterone. Data are means of three independent experiments 
 with four repeats each. ***P< 0.0001 
 
4.3.3 Evaluation of OCT1 mediated cytotoxicity of paclitaxel using the MTT assay 
Treatment of OCT1 expressing cells with 100 µM paclitaxel effected a 30.67 ± 3.29%, P< 
0.05 decrease in cell viability (Figure 4.45). This was significantly reversed on simultaneous 
treatment with paclitaxel and TEA, and paclitaxel and corticosterone to 106.79 ± 1.3% and 
99.02 ± 3.41%, respectively. OCT1 expressing cells also exhibited increased cell viability 
when treated with TEA and corticosterone (110 ± 2.39%, P< 0.05 and 113.12 ± 0.89%, P< 
0.05, respectively). No significant changes in cell viability of mock cells were observed. 





















































































Fig 4.45 Cell viability test for OCT1 expressing cells after paclitaxel treatment. The test was 
performed using the MTT colorimetric assay. Cells were treated with 100 µM of the cytostatic for 
15 min, washed with PBS and incubated overnight in cell culture medium at 37 °C. Data are means of 
three independent experiments with four repeats each. * P< 0.05 
 
In B-lymphoma cells lines treated under similar conditions, SUDHL-4 did not show any 
changes in cell viability (Figure 4.46). OCT1 expressing L-428, however, exhibited a 
decrease in cell viability by 45.71 ± 4.5% on paclitaxel treatment alone. Treatment of L-428 
with paclitaxel and TEA resulted in a significant recovery of cells (47%) with the reduced cell 
viability of only 18.44 ± 5.39%. The recovery of cells on incubation with paclitaxel and 
corticosterone was also highly significant, with the decrease in cell viability calculated to be 
only 9.96 ± 5.66%.  























































































 Fig 4.46 OCT1 mediated cytotoxicity of paclitaxel was determined using the MTT assay 
 in the B- lymphoma cell line, L-428. SUDHL-4, with no observed expression of OCT1, was 
 used as a control. Cells were treated with 100 µM paclitaxel for 15 min, washed with PBS and 
 incubated in cell culture medium for an additional 24 h at 37 °C. Paclitaxel toxicity in L-428 
 was partially reversed by the addition of TEA and corticosterone. Data are means of three 
 independent experiments with four repeats each. * P< 0.05, **P<0.001, ***P< 0.0001 
 
4.4 p53 expression analysis 
The tumour suppressor, p53, is responsible for the transcriptional activation of a series of 
proteins involved in apoptosis. This protein is present at low levels in resting cells, but 
exposure to DNA- damaging agents stabilizes and activates p53. We looked for changes in 
p53 expression by quantifying the expressed protein under different conditions (control, 100 
µM specific cytostatic, 2 mM TEA, 100 µM corticosterone, cytostatic + TEA, cytostatic + 
corticosterone). Cells were incubated in different conditions for 15 min and allowed to 
recover for 1 h at 37°C. Western blots for p53 expression analysis were probed with mouse 
anti-p53 (1:1000) and with mouse anti-actin (1:1000) for normalization.  
 




4.4.1 Evaluation of p53 expression on irinotecan treatment  
Western blot analysis revealed that 15 minutes treatment of OCT1 and OCT2 expressing cells 
with irinotecan did not result in an elevation of steady state levels of the p53 protein (Figure 
4.47). No changes were seen in irinotecan treated cells from untreated cells.  



















 Fig 4.47 p53 expression on irinotecan treatment in OCT1 and OCT2 expressing cells.  
 Cells were treated with normal media ø, irinotecan I, TEA T, corticosterone C, 
 irinotecan+TEA I+T and irinotecan+corticosterone I+C, for 15 minutes. Following 1 h 
 recovery, cells were lysed and gels run.  
4.4.2 Evaluation of p53 expression on mitoxantrone treatment 
Treatment of OCT1 cells with mitoxantrone gave a slight shift in the p53 protein band. This 
upward shift in the signal for p53 was also seen in samples treated with mitoxantrone together 
with TEA and corticosterone (Figure 4.48).  
The control cells revealed a steady state expression of p53 with no changes under any 
condition tested. A slightly higher expression of p53 with mitoxantrone alone could be due to 
higher protein loaded for this sample as demonstrated by a slightly stronger actin signal. 

















 Fig 4.48 p53 expression on mitoxantrone treatment in OCT1 expressing cells.  Cells were 
 treated with normal media ø, mitoxantrone M, TEA T, corticosterone C, mitoxantrone+TEA 
 M+T and mitoxantrone+corticosterone M+C, for 15 minutes. Following 1 h recovery, cells 
 were lysed and gels run. Blots were probed for p-53 expression using mouse anti-p53 
 (1:1000). 
4.4.3 Evaluation of p53 expression on paclitaxel treatment  
p53 expression in OCT1 cells on paclitaxel treatment alone did not change from control 
conditions (Figure 4.49). However, TEA and corticosterone treatment of OCT1 cells gave 
much weaker p53 signals.  
The control cells exhibited a constant p53 expression under different conditions. Paclitaxel in 
the presence of corticosterone gave a weaker signal for p53, but this can be explained by a 















 Fig 4.49 p53 expression on paclitaxel treatment in OCT1 expressing cells.  Cells were 
 treated with normal media ø, paclitaxel P, TEA T, corticosterone C, paclitaxel+TEA P+T and 
 paclitaxel+corticosterone P+C, for 15 minutes. Following 1 h recovery, cells were lysed and 
 gels run. Blots were probed for p-53 expression using mouse anti-p53 (1:1000). 
 




4.5 Uptake of [
14
C]succinate by NaDC3- FlpIn T-Rex HEK 293 
To determine whether the NaDC3 cell line generated expressed the functional protein, we 
measured the uptake of radiolabelled succinate, a known substrate of NaDC3 (Figure 4.50). 
The stably transfected cells expressing NaDC3 exhibited an uptake of 93920.30 ± 2351.61 
fmol/ 5 min, which was 95% higher than mock cells (2922.02 ± 751.48 fmol/ 5 min). This 
uptake was reduced to 10.33 ± 0.67%, P< 0.0001 (9704.45 ± 629.77 fmol/5 min) by the 
addition of 1 mM cold succinate. Lithium is known to inhibit transport via NaDC3 and the 
addition of 10 mM lithium into the transport medium reduced the uptake of succinate by 
51.88 ± 4.04%, P< 0.0001 (46226.22 ± 3798.23 fmol/ 5 min). Since NaDC3 relies on Na+ to 
effect transport, we also checked for transporter activity in the absence of Na+ in transport 
medium. Na+ free transport medium effectively abolished NaDC3 activity (4106.58 ± 599.80 










































































 Fig 4.50 [
14
C]succinate uptake by NaDC3. The uptake was significantly inhibited by 
 unlabelled succinate, in the absence of sodium in the uptake medium and in the presence 
 of lithium. Data are means of three independent experiments with four repeats each. 
  ***P<  0.0001 
 




4.6 Cis-Inhibition of NaDC3 mediated [
14
C]succinate uptake  
The interaction of cytostatics with NaDC3 was determined by inhibition of [14C]succinate 
uptake by these cells (Figure 4.51). Twelve cytostatics were tested and succinate uptake was 
significantly inhibited by 100 µM methotrexate to 76.1 ± 1.16%, P< 0.05. Another 
antimetabolite, gemcitabine, also reduced succinic acid uptake by NaDC3 by 30.5 ± 0.78%, 
P< 0.001. Nearly 20% inhibition of succinate uptake by NaDC3 was also observed with 
busulfan, irinotecan, paclitaxel, fludarabine, mitoxantrone, cladrabine and fluoroadenine; but 
this inhibition was not significant. Prednisone stimulated uptake of succinate by NaDC3 to 





































































































































  Fig 4.51 Inhibition of NaDC3 mediated [14C]succinate uptake by various cytostatics 
 (100 µM). Cells expressing hNaDC3 were incubated in transport medium for 5 min. All 
 experiments were standardized by setting the control (without cytostatic) to 100 %. Data are 
 means of three independent experiments with three repeats each. * P< 0.05, **P< 0.01 
 
The inhibition observed with methotrexate and gemcitabine was much lower than 50% and 
therefore, the drug kinetics with NaDC3 were not examined further. 





The successful treatment of cancer involves an effective uptake of chemotherapeutic agents 
into cancer cells, mediated by transporter proteins. An increased expression of drug exporting 
proteins, like MDR1 and MRPs results in chemoresistance of cancer cells. This 
chemoresistance could possibly be overcome by using cytostatics specific for certain uptake 
transporters present in tumour cells. Although there has been a growing interest in SLC 
transporters over the years, not much is known about the interaction of tumour treating drugs 
with these transporters. Therefore, the aims of the present study were to examine the 
expression of SLC transporters in lymphoma cell lines and in CLL patient samples, the 
interaction of cytostatics with specific transporters; and finally, the transporter mediated 
cytostatic effect of these drugs on tumour cells. 
In recent years, ATP-binding cassette (ABC) transporters related to multidrug resistance 
(MDR), such as P-glycoprotein (MDR1) and ABCG2 (breast cancer resistance 
protein/mitoxantrone resistance protein) have emerged as key factors that regulate the 
intracellular concentrations of many therapeutics. Drug transporters may be overexpressed in 
cancer cells reducing intracellular drug concentrations (117). For example, MDR1 has been 
shown to reduce doxorubicin access to nuclear targets in cells (106). MDR1 and MRP1 were 
expressed at high levels in all lymphoma cell lines we tested. Since chemoresistance is 
mediated in part by the efflux of cytostatics by these transporters, the expression levels of 
ABC transporters in cancer cells should be considered during tumour therapy.  
5.1 Expression of uptake transporters belonging to the SLC family in lymphoma cell 
lines and CLL patient samples 
Total cell RNA was purified from six lymphoma cell lines and from the peripheral blood of 
CLL patient samples. Following reverse transcription, PCR was carried out. As a target of 
cytostatics, expression levels of different SLC transporter families were analyzed.  
The ubiquitous system L transporters, LATs (SLC7) mediate the transfer of large, neutral 
amino acids across plasma membranes (59). LATs occur ubiquitously in the body and the 
tissue distribution of LAT1 suggests that it is expressed in growing cells, a fact that may be 
utilized in transporting drugs into cells. Melphalan, used in chronic lymphocytic leukaemia 
treatment, is also known to be transported by LAT1 into the cells (124). We observed a high 
expression of LAT1 in all six cell lines tested, which may make these cells sensitive to 




cytostatic analogs of L-amino acids. However, our results demonstrated a high expression of 
LAT1 in healthy lymphocytes as well. This high expression of LAT1 in healthy cells makes 
the use of LAT1 specific cytostatics difficult since it would result in the death of healthy cells.  
The SLC10 transporters, NTCP and ASBT are essential in maintaining the enterohepatic 
circulation of bile acids. NTCP mediates the transport of bile acid in the liver while ASBT 
transports bile acid through the membrane in the intestine (68;79). SLC10 transporters can 
provide an effective means of cellular uptake of bile-conjugated drugs for therapy and NTCP 
is a known transporter of the drug-conjugate chlorambucil-taurocholate (67). However, we 
did not observe SLC10 transporter expression in our cell lines and thus these transporters are 
not viable for use in transporter-specific tumour therapy for lymphomas.  
The SLC13 family transporters are found in plasma membranes of mammalian cells. NaDC3 
is found in kidneys, placenta, liver and brain. Substrates include dicarboxylates essential in 
the citric acid cycle, like α-ketoglutarate (88). In the brain, NaDC3 mediates the transport of 
N-acetylaspartate,  and benzylpenicillin is also known to interact with NaDC3 (15). Transport 
of cytostatics by NaDC3 has not been reported so far, although the presence of this transporter 
in brain and kidneys makes it a viable target for selective therapy of brain and kidney 
tumours. The expression of NaDC3 was not seen in lymphoma cell lines and therefore cannot 
be a target for limiting tumour cell growth.  
The monocarboxylate transporters belonging to the SLC 16 family, MCTs, are expressed 
ubiquitously in the human body (45;93) and catalyze the transport of monocarboxylates 
including lactate and pyruvate (46). The interaction of MCT2 with ifosphamide metabolites 
has also been reported (20) and the transport of other drugs like valproic acid may also be 
mediated by MCTs (53). MCT1 and MCT4 require CD147 for proper cell surface expression 
and function. CD147 is a member of the immunoglobulin superfamily and is also up-
regulated in aggressive tumours (119). The interaction of MCTs with cytostatics makes them 
important candidates in the uptake of cancer treating drugs and their resultant cytotoxicity. 
MCT1, MCT2 and MCT4 were all expressed at high levels in lymphoma cell lines. MCT1 
and MCT4 were also expressed at high levels in healthy lymphocytes. MCT2 was expressed 
at lower levels in healthy lymphocytes and may be considered in mediating ifosphamide 
based therapy. However, MCT transporters are very important for cell survival and this makes 
these transporters unsuitable for transporter-mediated therapy. Real time analysis of MCT4 




expression in CLL patient samples also revealed a much lower MCT4 expression than in 
healthy lymphocytes, thus negating this transport for use in tumour therapy.  
The folate/thiamine transporter family, SLC19, includes the reduced folate transporter (RFT). 
RFT expression is seen in all human tissues, although it is much higher in absorptive tissues 
like intestine, kidney and placenta. RFT mediates the cellular influx of folate and its 
derivatives. The transporter also mediates the transport of the antineoplastic methotrexate. 
Mutations in RFT can lead to chemoresistance to antifolates like methotrexate (35). The 
thiamine transporter, ThTr1, is expressed ubiquitously and may be used to transport thiamine-
conjugated drugs. RFT and ThTr1 were found to be expressed at slightly higher levels in the 
lymphoma cell lines than in healthy samples, making these transporters candidates for 
antifolate cytostatic therapy.  
Organic anion transporting polypeptides, OATPs, belong to the SLCO family of transporters 
and are expressed in a variety of tissues, including intestine, liver, kidney and brain (64). 
These mediate the uptake of a broad range of compounds into the cells, including bile salts, 
hormones and steroid conjugates (35). OATPs play a critical role in drug absorption, 
distribution and excretion. Due to their wide tissue distribution and broad substrate spectrum, 
altered protein localization and transport characteristics can contribute to interindividual 
variations of drug effects. Bamet-UD, a cisplatin derivative, is transported by OATP-A (13) 
and SN-38, the active metabolite of irinotecan, has been shown to interact with OATP-C (85). 
OATP8 transports cytostatics like methotrexate and paclitaxel (108). OATP-B was found to 
be expressed in only B-lymphoma cell lines with no expression seen in healthy cells. 
Therefore, this transporter could be used for specifically targeting B-lymphoma cells. 
However, in CLL patient samples, OATP-B expression was not observed at all, thus opposing 
the use of OATP-B specific cytostatics in treatment. OATP-D was also expressed at much 
higher levels than normal in the lymphoma cell lines and may be a candidate for transporter 
therapy. OATP-E was expressed at higher levels than normal in the cell lines but was 
expressed at much lower levels in CLL patient samples. Therefore, OATP-E cannot be 
considered for use in tumour therapy.  
The SLC22 family includes the organic cation transporters, OCTs. Expressed in many tissues 
like the kidney, liver and the blood-brain barrier, OCTs transport positively charged 
endogenous substrates (epinephrine, norepinephrine) and exogenous substrates (MPP, TEA) 
(17). OCTs are also involved in drug distribution and are known to mediate drug transport 




across the blood-brain barrier (105). Cisplatin, a platinum based cytostatic, is specifically 
transported by OCT2 (26). Recently, our lab has demonstrated the involvement of OCT3 in 
the uptake of three cytostatics- irinotecan, melphalan and vincristine and the OCT3 mediated 
cytotoxicity of these drugs in Renal Carcinoma cell lines (107). OCT6 has been shown to 
transport doxorubicin, used in carcinoma therapy (87). Using real time analysis, we found that 
OCT1 was expressed at higher levels in lymphoma cell lines than in healthy lymphocytes. In 
CLL patient samples too, OCT1 was expressed at much higher levels than in healthy 
lymphocytes, making it a prime candidate for transporter mediated tumour therapy. OCT6 
was also expressed at much higher levels in lymphoma cell lines as well as in CLL patient 
samples than normal. OCT6 can thus be considered for tumour therapy.  
Organic anion transporters, OATs, are located at boundary epithelia and play an important 
role in distribution and excretion of drugs. The antimetabolite cytostatic, methotrexate, is 
known to be transported by OAT1, 2, 3 and 4 (118). OAT2 is also known to transport the 
cytostatic 5-fluorouracil (61). Unpublished studies in our group have demonstrated the 
interaction of chlorambucil with OAT1, 3 and 4; and a specific interaction of bendamustine 
with OAT3 (PD Dr. Yohannes Hagos, personal communication). While OAT1 was expressed 
at higher levels than normal in the lymphoma cell lines, much lower expression than normal 
was observed for OAT1 in CLL patient samples. The same was true for OAT2 where the 
expression was high in lymphoma cell lines but no expression was observed in CLL patient 
samples. Thus, OAT transported drugs cannot be considered for therapy in this case, since the 
application of these cytostatics may result in major side effects rather than efficient tumour 
treatment.  
The sodium-coupled concentrative nucleoside transporters of the SLC 28 family, CNTs, 
transport nucleosides and nucleoside analogs actively into cells. CNTs are pharmacologically 
important as they transport many clinically relevant drugs. CNT1, which is expressed in the 
liver, kidney and small intestine, is a known transporter of cytotoxic cytidine analogs 
cytarabine and gemcitabine, used in the treatment of tumours (40). CNT3, occurring 
ubiquitously in the body, transports many anticancer nucleoside analogs like cladribine, 
gemcitabine and fludarabine (98;99). However, no observable expression of CNTs was seen 
in the lymphoma cell lines thus making these transporters unsuitable for use in tumour 
therapy.  




Most mammalian cells express equilibrative nucleoside transporters (ENTs) belonging tot he 
SLC 29 family. ENTs play key roles in nucleoside and nucleobase uptake (42). ENTs are 
implicated in the cellular uptake of nucleoside analogues used in cancer treatment and also in 
the treatment of viral diseases. ENT2 has a great capacity to transport clinically important 
drugs used in HIV therapy, like 3’-azido-3’-deoxythymidine (AZT) (125). ENTs, in particular 
ENT1, play a critical role in the uptake of many cytotoxic nucleoside analogues like 
cladribine, cytarabine, fludarabine and gemcitabine (28). High ENT1 expression may 
contribute to the selectivity of nucleoside chemotherapy for malignant cells and the in vitro 
sensitivity of acute lymphoblastic leukaemia cells to cladribine has been attributed to these 
transporters (28). Conversely, a lowered expression of these transporters may contribute to 
drug resistance for cytotoxic nucleoside analogues. Expression measurement of these 
transporters can thus provide a valuable tool in guiding cancer therapy. While the ENT 
expression was high in the lymphoma cell lines tested, lower than normal expression was seen 
in CLL patient samples. Nucleoside analogs (eg. fludarabine) are successfully used in CLL 
therapy; however, the cytotoxic effect of these drugs may not be ENT-dependent.   
The transporter expression studies made by us in CLL patient samples may be limited by the 
improper collection of patient samples and the handling thereafter (eg. freezing of samples). 
In addition, results may be affected by the medical history of patients. Substrate induction for 
transporters has been shown previously (81). It is possible that changes in transporter 
expression take place as a result of cytostatics used in the treatment regimen. Understanding 
the expression changes in transporters can also potentially help in generating safer treatment 
regimen by predicting changes in drug pharmacokinetics.  
5.2 Interaction of cytostatics with OCT1 and OCT2 
The electrogenic organic cation transporters 1 and 2 are expressed in the liver, kidney, brain 
and the intestines (63); and translocate a variety of organic cations with widely differing 
molecular structures. Substances transported by the OCT transporters include organic cations 
and weak bases which are positively charged at physiological pH. Non-charged compounds 
may also be transported, as has been demonstrated for cimetidine transport (63). 1-Methyl-4-
phenylperidinium (MPP) and tetraethylammonium (TEA) are model cations transported by 
OCT1, OCT2 and OCT3. The OCT transporters are inhibited by a variety of compounds 
which may not be transported themselves. Inhibitors of OCT transport include cations like 




tetrapentylammoniun, noncharged compounds like corticosterone and anions like probenecid 
(63).  
The high expression of OCT1 in lymphoma cell lines as well as in CLL patient samples 
makes it a suitable candidate for drug targeting. OCT1 and 2 mediated transport for drugs like 
the antidiabetic metformin and the antimalarial drug quinine has been previously reported. 
OCT1 also transports antivirals like aciclovir and ganciclovir. Among the cancer treating 
drugs, cisplatin has been identified as an OCT2 substrate and its transport demonstrated (63).  
To confirm the functionality of OCT1 and OCT2 in stable transfected cells, we performed 
experiments with the known substrate of organic cation transporters, MPP. Using increasing 
concentrations of [3H]MPP, we determined 20 nM MPP to be efficiently transported in OCT1 
and OCT2 cells. [3H]MPP uptake was inhibited by the addition of cold MPP (50-500 µM) to 
the transport medium. The high ratio of hot and cold MPP in the transport medium results in a 
very low uptake of radiolabelled (hot) MPP uptake. 
 We next performed a series of experiments to test the inhibition potency of cytostatics for 
OCT1 and OCT2 mediated [3H]MPP uptake. The interaction of cytostatics with OCT3 was 
previously studied in our group and demonstrated the interaction of irinotecan, vincristine and 
melphalan with OCT3 (107). For our experiments, we selected substances covering the major 
groups of cytostatics used in chemotherapy. Among the 22 cytostatics we tested, irinotecan, 
mitoxantrone and paclitaxel inhibited OCT1 mediated [3H]MPP uptake by more than 50%. In 
OCT2 expressing cells, irinotecan effectively inhibited more than 50% [3H]MPP uptake. 
Irinotecan, thus, interacts with OCTs 1, 2 and 3 while paclitaxel and mitoxantrone interact 
with only OCT1.  
The interaction of these three cytostatics was analyzed using Dixon plot studies. Irinotecan 
interacted with OCT1 in a competitive manner while the interaction of mitoxantrone and 
paclitaxel with OCT1 was non-competitive. OCT1 showed a high affinity for irinotecan, with 
a Ki value of only 1.73 µM. The observed affinity of OCT1 was relatively low for 
mitoxantrone and paclitaxel, with calculated Ki values of 85.2 µM and 50.1 µM, respectively. 
The interaction of irinotecan with OCT2 was also analyzed and was determined to be mixed 
inhibition. OCT2 showed a much lower affinity for irinotecan with a Ki value of 86.3 µM. 
While irinotecan may be transported by OCT1, results for mitoxantrone and paclitaxel suggest 
that these two cytostatics do not occupy the substrate recognition site and are not transported. 




Similarly, the results with OCT2 suggest that while the transporter interacts with irinotecan, it 
does not transport the cytostatic. However, deviations from the classical competitive 
inhibition have been observed and we cannot exclude the transport of mitoxantrone and 
paclitaxel by OCT1 and that of irinotecan by OCT2.  
Although the lymphoma cell lines we tested demonstrated a strong OCT1 expression, it was 
not possible to carry out uptake studies in these suspension cells. High background of 
radioactivity was measured during uptake in suspension cells which interfered with the 
measurement of incorporated radioactivity. The methodology for uptake measurements in 
suspension cells involved the use of silicon oil which should theoretically draw the non-
incoporated radioactivity. However, a high background of radioactivity was measured even 
after the removal of the silicon oil. The elimination of the oil itself was rather inefficient with 
small amounts present in the samples, adding to the measured radioactivity.  
5.2.1 Transporter mediated cytotoxicity of irinotecan 
OCT1 and OCT2 mediated [3H]MPP uptake was efficiently inhibited by the addition of 
irinotecan to the transport media in stably transfected cells. Irinotecan is a topoisomerase I 
inhibitor and is used as a first-line therapy in metastatic colorectal cancer in combination with 
other drugs (103). Irinotecan is converted by hydrolysis to its active metabolite, SN-38, which 
undergoes glucuronide conjugation to the pharmacologically inactive SN-38 glucuronide, SN-
38G (56). As a topoisomerase I inhibitor, SN38 inactivates topoisomerase I enzyme activity, 
leading to a ‘locking’ of topoisomerase I on DNA. The topoisomerase I-DNA complex 
formed blocks DNA duplication and RNA transcription.  
SN-38 treatment makes cells sensitive to other cytostatics and irinotecan cytotoxicity is 
dependent on the concentration of active SN-38 in cells. This SN-38 concentration in cells is 
modulated by the hydrolase enzyme responsible for the hydrolysis of irinotecan to SN-38 as 
well as the glucuronosyltransferase which converts SN-38 into its inactive form (56). The 
concentration of SN-38 is also dependent on the efflux of the irinotecan metabolite out of 
cells by MDR1 while the influx may be regulated by specific uptake transporters.  
In the MPP uptake inhibition experiments, we demonstrated an interaction of irinotecan with 
OCT1 and OCT2. To test whether the expression of OCT1 and OCT2 affected cell 
proliferation on treatment with irinotecan, we carried out MTT assays. Cell proliferation was 
significantly inhibited in OCT1 and OCT2 expressing CHO cells treated with irinotecan 




compared to control cells that do not express OCT1 or OCT2. To prove that the cytotoxic 
effect of irinotecan is dependent on OCT1 and OCT2 activity, we inhibited irinotecan uptake 
into our cells by 2 mM TEA. TEA, tetraethylammonium, is a substrate of OCTs and the OCT 
mediated transport into cells has been previously demonstrated (63). OCT1 and OCT2 
expressing CHO cells which were treated with irinotecan in the presence of TEA did not 
demonstrate lowered cell viability. Treatment with irinotecan in the presence of 100 µM 
corticosterone, an inhibitor of OCT-mediated uptake, did not affect cell viability in OCT1 and 
OCT2 expressing cells. These results suggest that irinotecan is indeed transported by OCT1 as 
well as OCT2 and can explain the lowered cell viability in OCT expressing cells. 
To test whether irinotecan could be used in the treatment of lymphomas expressing OCT1 or 
OCT2, we performed similar experiments using two B-lymphoma cell lines. Our previous 
studies on expression of OCTs revealed a high OCT1 expression in the B-lymphoma cell line 
L-428 while no expression for OCT1 was observed in SUDHL-4 cells. OCT2 expression was 
not observed in any cell line. Since irinotecan transport is also mediated by OCT3 in renal 
carcinoma cell lines and the resultant cytotoxicity demonstrated previously (107); we tested 
OCT3 expression in lymphoma cell lines and found no observable expression of OCT3. 
Irinotecan cytotoxicity tests revealed a comparatively higher sensitivity in OCT1 expressing 
L-428. This sensitivity to irinotecan, read as lowered cell viability of L-428 cells, was slightly 
inhibited on treatment with irinotecan in the presence of TEA and corticosterone. In the OCT 
deficient cell line, SUDHL-4, no effect on cell viability was observed. These results again 
suggest that OCT1 is responsible for the transport of irinotecan into cells and the selective 
lowering of cell viability in OCT1 expressing L-428 cells may be explained by the cytotoxic 
action of irinotecan on these cells.  
The relatively lower degree of the reversal in cytotoxicity on the application of irinotecan in 
the presence of TEA and corticosterone may be due to the uptake of irinotecan by some other 
transporter. Studies in our lab have demonstrated the interaction of MATE1 with irinotecan 
and SN-38 (the active metabolite of irinotecan) has also shown to be a substrate for OATP8 
(OATP1B3) (123). It may be worthwhile to investigate the expression of MATE1 and OATP8 
in our lymphoma cell lines. 
The reduction in cell viability observed in both, the stably transfected CHO cells expressing 
OCT1 and OCT2, as well as in the lymphoma cell line, L-428, was less than 60 %. This could 
be explained by the relatively short incubation time of only 15 minutes. Cells were incubated 




for only 15 minutes under different conditions to ensure that the observed effects were due to 
active uptake and thus transporter dependent. Cytotoxicity assays are usually done by 
exposing cells to various drug concentrations for 24-72 h (66). However, using this short 
incubation time, we could theoretically rule out diffusion of the drug into cells. Another 
possible reason for the relatively lower reduction in cell viability seen in our experiments is 
the efflux of irinotecan by the ABC transporters. We tried inhibiting the efflux of irinotecan 
by applying verapamil, MDR inhibitor, to our cells. However, the inhibition of MDR proved 
toxic to cells and lowered cell viability was observed for OCT expressing as well as non-
expressing cells even in the absence of irinotecan. Therefore, verapamil was not used in 
further experiments.  
We also carried out [3H]thymidine incorporation experiments as a measure of inhibition of 
DNA synthesis in irinotecan treated OCT1 and OCT2 expressing stably transfected cells. 
However, in our experiments we could not demonstrate a clear inhibition of cell proliferation 
using this method. One possible reason for the absence of clear DNA synthesis inhibition 
could be the incorporation of radioactivity from [3H]thymidine into macromolecules other 
than DNA (58).  
As an additional readout of irinotecan cytotoxicity on our cells, we screened the expression of 
p53 by treated cells. The p53 tumour suppressor is a critical transcription factor. It controls 
cell growth and induces apoptosis during cellular stress (65). Transactivation of target genes 
under the control of p53 is an essential step in stress response (120). We carried out 
experiments on stably transfected OCT1 and OCT2 cells treated with irinotecan, in the 
presence and absence of TEA and corticosterone. p53 expression under different conditions 
was examined and we found that after 15 minutes of treatment, steady state levels of p53 did 
not change. Irinotecan, via its active metabolite, SN-38, has been demonstrated to 
significantly increase the expression of p53 and its phosphorylation, alongwith increased 
expression of apoptosis-inducing proteins, Bax, caspase-9 and caspase-3 (111). The increased 
expression of p53 was observed by Takeba et al. after 24 h treatment with irinotecan. The 
absence of elevated p53 levels in treated cells may be due to the absence of immediate 
activation of apoptosis after only 15 minutes of treatment. The active efflux of irinotecan by 
MDR1 may also account for the absence of changes in p53 levels seen in our experiments. 
The increased expression of MDR1 has previously been shown to inhibit irinotecan-induced 
apoptosis (112). To test the role of p53 dependent cellular response to DNA damage, it would 




be worthwhile to examine the expression of p53 regulated genes like p21. Alternatively, the 
cells may exhibit a p53-independent response to irinotecan treatment. Although the 
mechanism is not clear, our experiments demonstrate that despite the failure of irinotecan to 
induce programmed cell death, it does reduce cell viability in OCT1 and OCT2 treated cells, 
as shown using the MTT assay.  
We suggest that the sensitivity of cells to irinotecan is dependent on OCT1. A positively 
charged compound, irinotecan shares partial structural similarity to MPP, the OCT substrate. 
This similarity to MPP structure may explain the interaction and suggested transport of 
irinotecan by OCT1. TEA and MPP binding in OCT1 is mediated by amino acids in the 
fourth transmembrane helix, an area located in the large cleft (16). This large cleft is easily 
accessible for organic cations, and may also recognize irinotecan. With a high affinity of 
OCT1 for irinotecan, the cytotoxicity of this cytostatic may be used in tumour cells 
expressing OCT1.  
Since the lymphoma cell lines available to us did not express OCT2, we could not confirm an 
OCT2 mediated irinotecan sensitivity on lymphoma cells. However, OCT2 may also play a 
role in irinotecan sensitivity as demonstrated by experiments on stably transfected cells. The 
comparatively lower affinity of OCT2 for irinotecan may be explained by differences in the 
substrate recognition regions of OCT1 and OCT2. Further experiments are needed to confirm 
irinotecan uptake by OCT2 and its usefulness in therapy. 
5.2.2 Transporter mediated cytotoxicity of paclitaxel 
OCT1 mediated [3H]MPP uptake was inhibited in CHO cells by the addition of paclitaxel to 
transport media. Paclitaxel is active against a broad range of cancers like lung cancer, and 
head and neck cancer. It is used in palliative therapy of ovarian and breast cancers resistant to 
chemotherapy (102) . This taxane works by promoting the polymerization of tubulin (104). 
Polymers of tubulin form microtubules which are responsible for the formation of the mitotic 
spindle during cell division. Microtubules are also involved in interphase functions, like 
maintenance of shape, motility and intracellular transport (33). Paclitaxel inhibits the 
disassembly of microtubules at subnanomolar concentrations. At higher concentrations, 
paclitaxel increases the mass and number of microtubules. Paclitaxel induced microtubules 
are particularly stable and dysfunctional, causing cell death by disrupting normal microtubule 
dynamics required for cell division and interphase functions (102). 




Some tumours express alpha- and beta-tubulin with an impaired ability to polymerize. 
Polymerization of tubulin in these tumour cells is very slow and is normalized by the 
application of paclitaxel (102). Resistance to paclitaxel may also be due to the activity of 
drug-efflux pumps like MDR1. The organic anion transporting polypeptide 8, OATP8 is a 
known transporter of paclitaxel and polymorphisms in the gene encoding this transporter may 
play crucial roles in the elimination of paclitaxel from cells (108). SLC transporters are also 
exchangers and OATP-8 may also contribute to chemoresistance in this case by exporting 
drugs out of the cell.  
Our experiments showed an interaction of paclitaxel with OCT1 by significantly inhibiting 
MPP uptake by OCT1 expressing cells. To test whether this inhibition of [3H]MPP uptake 
was actually due to transport of the cytostatic into cells, we measured the decrease in cell 
proliferation on application of paclitaxel. Stably transfected CHO cells expressing OCT1 were 
incubated with paclitaxel and this resulted in a 30 % lowered cell viability. To confirm the 
OCT1 dependent activity of paclitaxel on cells, we incubated cells with paclitaxel in the 
presence of TEA, a substrate of OCTs and corticosterone, an inhibitor of OCTs. Cell viability 
was not reduced in these samples.  
The B-lymphoma cell lines, L-428 and SUDHL-4, were also tested for OCT1 mediated 
cytotoxicity of paclitaxel. The OCT1 expressing L-428 demonstrated reduced cell viability by 
35 % while SUDHL-4, which does not express OCT1, was not affected. The reduced cell 
viability was partially reversed on application of the OCT1 substrate TEA together with 
paclitaxel. The OCT inhibitor corticosterone also effectively reversed the lowered cell 
viability seen in OCT1 expressing L-428 with paclitaxel alone. These results indicate that 
OCT1 mediates the uptake of paclitaxel into cells and its resultant cytotoxic action.  
The relatively lower reduction in cell viability in the MTT assays can be explained by the 
short incubation time of cells under different conditions and also due to the export of 
paclitaxel out of the cells by MDR1. Paclitaxel is a known substrate of MDR1 (78). The 
inhibition of MDR1 was done by the application of verapamil, but this proved toxic to OCT1 
expressing as well as non-expressing cells. Therefore, experiments were carried out without 
inhibiting MDR1.  
[3H]Thymidine incorporation experiments in stably transfected OCT1 cells were again 
inconclusive with no clear reduction in cell viability of treated OCT1 cells. This may again be 




due to high background levels of non-incorporated [3H]thymidine, similar to [3H]thymidine 
incorporation in irinotecan treated cells explained in the previous section.  
Previous studies have shown that microtubule inhibiting cytostatics activate the expression of 
p53 in cells (122). We examined the induction of p53 expression in OCT1 cells on paclitaxel 
treatment. We did not observe any changes in p53 expression under different conditions but 
this may be due to the short treatment time. It is possible that prolonged exposure to the 
cytostatic may result in higher p53 levels and thus induce immediate apoptosis. The 
maintenance of steady state p53 levels on paclitaxel treatment may also indicate that these 
levels are sufficient in activating cell cycle arrest, giving the cell time to repair the damage 
and thus avoid genetic instability.  
We hypothesize that paclitaxel transport and the resultant cytotoxicity is mediated by OCT1. 
OCT1 is also present in the bronchi of humans and OCT1 mediated paclitaxel transport can 
account for type I hypersensitivity reactions like bronchospasms that most patients experience 
on treatment with paclitaxel (102). There have also been reports of corticosteroid treatment to 
relieve this hypersensitivity (102) which may partially act by blocking the OCT1 mediated 
transport of the drug.  
An interaction of paclitaxel with OCT2 was also demonstrated but since the inhibition of 
MPP uptake affected was less than 50 %, this transporter was not studied for paclitaxel uptake 
studies. Nevertheless, OCT2 mediated paclitaxel transport is a viable area of study. Due to its 
expression in neurons, OCT2 transport of paclitaxel may also explain peripheral neuropathy 
observed in paclitaxel treated patients. While the expression of OATP8 in our cells was not 
tested, there are no reports to suggest that it is expressed in these cells. However, the role of 
OATP8 in paclitaxel uptake by these cells and its effect on cell death cannot be ruled out. One 
member of the OATP family, rat Oatp2, has been shown to function as a bidirectional organic 
solute transporter (74). It may well be that OATP8 functions as a paclitaxel-paclitaxel 
exchanger, although the affinities for this bidirectional transport may be different. Studies in 
our lab have also demonstrated the interaction of paclitaxel with OATP-B (Mr. Ronny 








5.2.3  Cytotoxicity of mitoxantrone is not OCT1 specific 
The addition of mitoxantrone to transport media resulted in a strong inhibition of OCT1 
mediated [3H]MPP uptake. Mitoxantrone is widely used against acute leukaemia, non-
Hodgkin and Hodgkin lymphomas, melanoma, liver cancer, prostate cancer, bladder cancer, 
and head and neck cancer (75). A topoisomerase II inhibitor, mitoxantrone induces DNA 
strand breaks (10;24). Structurally related to anthracycline antibiotics, mitoxantrone has been 
shown to be adsorbed by the plasma membranes of living cells (32). The breast cancer 
resistance protein, BCRP (ABCG2) facilitates the efflux of mitoxantrone from cancer cells 
(84).  
Mitoxantrone demonstrated an exceptionally high inhibition of MPP uptake by OCT1 cells 
and we therefore checked for OCT1 mediated transport of this cytostatic. Using MTT assays, 
we determined the effect of mitoxantrone on OCT1 expressing cells. Cell viability of these 
cells was reduced by 40 % while no effect was seen in mock cells.  
However, both the B-lymphoma cell lines tested for mitoxantrone sensitivity demonstrated 
reduced cell viability. The cell viability was reduced by more than 40 % in L-428 which 
expresses OCT1. SUDHL-4, which did not demonstrate any observable OCT expression, 
showed more than 60 % decrease in cell viability on mitoxantrone treatment. In both cell 
lines, this effect on mitoxantrone treatment was not reversible with TEA or corticosterone.  
These results lead us to conclude that mitoxantrone cytotoxicity seen in these cells is clearly 
not OCT1- specific. According to published data, mitoxantrone uptake into cells is not carrier 
mediated, but may occur due to simple diffusion and this may explain the cytotoxic effects 
seen in all cells treated with mitoxantrone (18). However, Pan and colleagues have recently 
demonstrated the role of influx transporters in mitoxantrone accumulation in cells. It has been 
suggested that mitoxantrone permeability in cells is not only affected by passive diffusion but 
also by an influx transporter (90). A lowered accumulation of mitoxantrone was observed at 
lower temperatures, similar to the uptake of the cytostatic imatinib, which was also found to 
be temperature dependent (113). OCT1 influx system has been suggested to play a role in 
imatinib transport. A putative mitoxantrone uptake transporter may belong to the SLC 
transporter family. With a positive charge at physiological pH, mitoxantrone may be 
transported by OCTs or OCTNs. However, mitoxantrone may not be selective substrate for 
OCTs, as demonstrated in our experiments. The cation and carnitine transporters 1 and 2, 




OCTN1 and OCTN2, are expressed in lymphocytes (63) and mitoxantrone uptake in the 
studied B-lymphoma cell lines may be attributed to OCTN- mediated transport. The 
interaction of drugs like levofloxacin with OCTN2 has been demonstrated (50).The uptake of 
L-carnitine, OCTN2 substrate is trans-stimulated by intracellular TEA (86). The uptake of 
TEA by OCT1 into cells may thus trans-stimulate OCTN2 mediated uptake of mitoxantrone 
into cells. The expression analysis of OCTN in our cell lines was not done and additional 
studies are needed to ascertain the influx transporter involved in mitoxantrone uptake.  
The expression of p53 in OCT1 cells on treatment with mitoxantrone revealed a slightly 
higher molecular weight band. This may well be a post translationally modified, for example, 
a phosphorylated form of p53. These up-shifted bands were also observed when mitoxantrone 
was applied to cells in the presence of TEA and corticosterone. Phosphorylation of p53 is 
regarded as the first step of p53 stabilization (65). These higher molecular weight bands may 
represent stabilized p53 in the cell which could then induce apoptosis. This would also 
support the high reduction in cell viability observed in the B-lymphoma cell lines on 
mitoxantrone treatment. It would be important to check the expression of p53 regulated 
factors that are functional in programmed cell death to confirm whether mitoxantrone 
cytotoxicity can really induce p53 activation.  
5.3 Interaction of cytostatics with NaDC3 
NaDC3 is a high affinity Na+/dicarboxylate transporter, encoded by SLC13A3 gene. With a 
broad tissue distribution, NaDC3 is found in renal proximal tubule cells, liver, brain and 
placenta (88). NaDC3 is responsible for transporting a range of substrates, including long 
chain or branched dicarboxylates. Substrates of NaDC3 include α-ketoglutarate and heavy 
metal chelators like dimercaptopropane-1-sulfonate (14). NaDC3 also mediates the high 
affinity transport of N-acetylaspartate in the brain (36). The transport of substrates by NaDC3 
is sodium-dependent and is electrogenic. Interaction with monovalent organic anions like 
benzylpenicillin has also been demonstrated (15). Human NaDC3 transport is inhibited by 
millimolar concentrations of lithium (121).  
NaDC3 is an important regulator of oxidative metabolism, but the pathophysiological 
implications and the mechanisms of expression of this high affinity Na+/dicarboxylate 
transporter are poorly understood. The use of the generated cell line in studying potential 




interaction partners may help in making the physiological and pathological roles of NaDC3 
clearer.  
Following the generation of stable transfected NaDC3 cell line, we examined the interaction 
of NaDC3 with various cancer treating drugs. Only methotrexate and gemcitabine inhibited 
NaDC3 mediated succinate uptake significantly. However, the inhibition achieved was less 
than 50 % and therefore these interactions were not studied further.  
5.4 Conclusions and outlook 
In the present study, we investigated the expression of uptake transporter proteins in cancer 
cells and the transporter mediated cytotoxic effects of cytostatics. The lymphoma cell lines 
studied demonstrated a variable expression of uptake transporters. The high expression of 
OCT1 in these cells could potentially be used for treatment with cytostatics like irinotecan 
and paclitaxel. The use of cytostatics specifically transported by OCT1 could help target these 
cancer cells better and thus, result in an effective treatment regimen. The lymphoma cell lines 
studied also expressed a variety of efflux ABC transporters. Inhibiting the efflux action of 
these pumps while simultaneously applying OCT1 specific drugs is one way of overcoming 
chemoresistance in cancer cells.  
The use of transporter-mediated cancer therapy has immense potential. Studying transporter 
expression in cancer cells, before as well as during, therapy can help tailor therapy to suit 
individual needs, while minimizing serious side effects.  





6.1 Vector maps 
 
 
                            
  




                    
 
  
                                   




7.  References 
 
 1.  Acimovic Y, Coe IR. Molecular evolution of the equilibrative nucleoside transporter 
family: identification of novel family members in prokaryotes and eukaryotes. 
Molecular Biology and Evolution 2002;19:2199-210. 
 2.  Ahmadi T, Maniar T, Schuster S, Stadtmauer E. Chronic Lymphocytic Leukemia: new 
concepts and emerging therapies. Curr.Treat.Options.Oncol. 2009. 
 3.  Au-Yeung BB, Deindl S, Hsu LY, Palacios EH, Levin SE, Kuriyan J et al. The 
structure, regulation, and function of ZAP-70. Immunological Reviews 2009;228:41-
57. 
 4.  Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative 
nucleoside transporter family, SLC29. Pflugers Archiv.European Journal of 
Physiology 2004;447:735-43. 
 5.  Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clinical 
Chemistry 2009;55:623-31. 
 6.  Bergeron MJ, Simonin A, Burzle M, Hediger MA. Inherited epithelial transporter 
disorders-an overview. J.Inherit.Metab Dis. 2008. 
 7.  Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C et al. 
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic 
leukemia: results of a phase I/II study of the German CLL Study Group. 
Haematologica 2005;90:1357-64. 
 8.  Biermann J, Lang D, Gorboulev V, Koepsell H, Sindic A, Schroter R et al. 
Characterization of regulatory mechanisms and states of human organic cation 
transporter 2. Am.J.Physiol Cell Physiol 2006;290:C1521-C1531. 
 9.  Boelens J, Lust S, Vanhoecke B, Offner F. Chronic lymphocytic leukaemia. 
Anticancer Research 2009;29:605-15. 
 10.  Boland MP, Fitzgerald KA, O'Neill LA. Topoisomerase II is required for 
mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. Journal of 
Biological Chemistry 2000;275:25231-8. 
 11.  Boonstra R, Timmer-Bosscha H, Echten-Arends J, van der Kolk DM, van den BA, de 
Jong B et al. Mitoxantrone resistance in a small cell lung cancer cell line is associated 
with ABCA2 upregulation. British Journal of Cancer 2004;90:2411-7. 
 12.  Borowski E, Bontemps-Gracz MM, Piwkowska A. Strategies for overcoming ABC-
transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochimica 
Polonica 2005;52:609-27. 
 13.  Briz O, Macias RI, Perez MJ, Serrano MA, Marin JJ. Excretion of fetal biliverdin by 
the rat placenta-maternal liver tandem. Am.J.Physiol Regul.Integr.Comp Physiol 
2006;290:R749-R756. 




 14.  Burckhardt BC, Drinkuth B, Menzel C, Konig A, Steffgen J, Wright SH et al. The 
renal Na(+)-dependent dicarboxylate transporter, NaDC-3, translocates dimethyl- and 
disulfhydryl-compounds and contributes to renal heavy metal detoxification. Journal 
of the American Society of Nephrology 2002;13:2628-38. 
 15.  Burckhardt BC, Lorenz J, Burckhardt G, Steffgen J. Interactions of benzylpenicillin 
and non-steroidal anti-inflammatory drugs with the sodium-dependent dicarboxylate 
transporter NaDC-3. Cell Physiol Biochem. 2004;14:415-24. 
 16.  Burckhardt G. Polyspecific organic cation transport: insights into the substrate binding 
site. Molecular Pharmacology 2005;67:1391-2. 
 17.  Burckhardt G, Wolff NA. Structure of renal organic anion and cation transporters. 
Am.J.Physiol Renal Physiol 2000;278:F853-F866. 
 18.  Burns CP, Haugstad BN, Mossman CJ, North JA, Ingraham LM. Membrane lipid 
alteration: effect on cellular uptake of mitoxantrone. Lipids 1988;23:393-7. 
 19.  Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we 
getting closer to understanding the pathogenesis of the disease? Journal of Clinical 
Oncology 2008;26:4497-503. 
 20.  Chatton JY, Idle JR, Vagbo CB, Magistretti PJ. Insights into the mechanisms of 
ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors and induce 
cellular acidification in mouse cortical neurons. Journal of Pharmacology and 
Experimental Therapeutics 2001;299:1161-8. 
 21.  Chekhun VF, Zhylchuk VE, Lukyanova NY, Vorontsova AL, Kudryavets YI. 
Expression of drug resistance proteins in triple-receptor-negative tumors as the basis 
of individualized therapy of the breast cancer patients. Exp.Oncol. 2009;31:123-4. 
 22.  Chen J, McMillan NA. Molecular basis of pathogenesis, prognosis and therapy in 
chronic lymphocytic leukaemia. Cancer Biol.Ther. 2008;7:174-9. 
 23.  Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. Journal of Clinical 
Oncology 2009;27:1492-501. 
 24.  Chiang SY, Azizkhan JC, Beerman TA. A comparison of DNA-binding drugs as 
inhibitors of. Biochemistry 1998;37:3109-15. 
 25.  Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. New England 
Journal of Medicine 2005;352:804-15. 
 26.  Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ et al. 
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 
2. American Journal of Pathology 2005;167:1477-84. 
 27.  Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. 
Biology of Blood and Marrow Transplantation 2009;15:523-36. 




 28.  Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE. The role of membrane 
transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treatment 
and Research 2002;112:27-47. 
 29.  Cotter FE, Auer RL. Genetic alteration associated with chronic lymphocytic leukemia. 
Cytogenet.Genome Res. 2007;118:310-9. 
 30.  Crazzolara R, Bendall L. Emerging treatments in acute lymphoblastic leukemia. 
Curr.Cancer Drug Targets. 2009;9:19-31. 
 31.  Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008;371:1017-29. 
 32.  Dubielecka PM, Trusz A, Diakowski W, Grzybek M, Chorzalska A, Jazwiec B et al. 
Mitoxantrone changes spectrin-aminophospholipid interactions. Molecular Membrane 
Biology 2006;23:235-43. 
 33.  Dustin P. Microtubules. Scientific American 1980;243:66-76. 
 34.  Fox CP, McMillan AK, Bishton MJ, Haynes AP, Russell NH. IVE (ifosfamide, 
epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE 
(ifosphamide, carboplatin and etoposide) in the context of salvage therapy for 
lymphoma. British Journal of Haematology 2008;141:244-8. 
 35.  Ganapathy V, Smith SB, Prasad PD. SLC19: the folate/thiamine transporter family. 
Pflugers Archiv.European Journal of Physiology 2004;447:641-6. 
 36.  George RL, Huang W, Naggar HA, Smith SB, Ganapathy V. Transport of N-
acetylaspartate via murine sodium/dicarboxylate cotransporter NaDC3 and expression 
of this transporter and aspartoacylase II in ocular tissues in mouse. Biochimica et 
Biophysica Acta 2004;1690:63-9. 
 37.  Geyer J, Wilke T, Petzinger E. The solute carrier family SLC10: more than a family of 
bile acid transporters regarding function and phylogenetic relationships. Naunyn 
Schmiedebergs Arch.Pharmacol. 2006;372:413-31. 
 38.  Giovannetti E, Mey V, Loni L, Nannizzi S, Barsanti G, Savarino G et al. Cytotoxic 
activity of gemcitabine and correlation with expression profile of drug-related genes in 
human lymphoid cells. Pharmacological Research 2007;55:343-9. 
 39.  Gora-Tybor J, Robak T. Targeted drugs in chronic myeloid leukemia. Current 
Medicinal Chemistry 2008;15:3036-51. 
 40.  Graham KA, Leithoff J, Coe IR, Mowles D, Mackey JR, Young JD et al. Differential 
transport of cytosine-containing nucleosides by recombinant human concentrative 
nucleoside transporter protein hCNT1. Nucleosides Nucleotides Nucleic Acids 
2000;19:415-34. 
 41.  Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, 
SLC28. Pflugers Archiv.European Journal of Physiology 2004;447:728-34. 
 42.  Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian 
cells. Biochimica et Biophysica Acta 1996;1286:153-81. 




 43.  Gulley J, Dahut WL. Clodronate in the prevention and treatment of skeletal 
metastasis. Expert.Rev.Anticancer Ther. 2005;5:221-30. 
 44.  Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ 
SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new 
nomenclature and molecular/functional properties. Pflugers Arch. 2004;447:653-65. 
 45.  Halestrap AP, Meredith D. The SLC16 gene family-from monocarboxylate 
transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers 
Archiv.European Journal of Physiology 2004;447:619-28. 
 46.  Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) 
family: structure, function and regulation. Biochemical Journal 1999;343 Pt 2:281-99. 
 47.  Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. 
British Medical Bulletin 2008;87:49-62. 
 48.  Hebbar M, Ychou M, Ducreux M. Current place of high-dose irinotecan 
chemotherapy in patients with metastatic colorectal cancer. Journal of Cancer 
Research and Clinical Oncology 2009;135:749-52. 
 49.  Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The ABCs of 
solute carriers: physiological, pathological and therapeutic implications of human 
membrane transport proteins. Pflugers Archiv.European Journal of Physiology 
2004;447:465-8. 
 50.  Hirano T, Yasuda S, Osaka Y, Kobayashi M, Itagaki S, Iseki K. Mechanism of the 
inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine 
transporter (OCTN2) in Caco-2 cells. Biochimica et Biophysica Acta 2006;1758:1743-
50. 
 51.  Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia 
chromosome-negative myeloproliferative disorders: biology and treatment. Biology of 
Blood and Marrow Transplantation 2007;13:64-72. 
 52.  Horn L, Sandler AB. Emerging data with antiangiogenic therapies in early and 
advanced non-small-cell lung cancer. Clin.Lung Cancer 2009;10 Suppl 1:S7-16. 
 53.  Hosoya K, Kondo T, Tomi M, Takanaga H, Ohtsuki S, Terasaki T. MCT1-mediated 
transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery 
of monocarboxylic acid drugs to the retina. Pharmaceutical Research 2001;18:1669-
76. 
 54.  Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer 
chemotherapy. Cancer and Metastasis Reviews 2007;26:183-201. 
 55.  Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I et al. A mutation in the 
drug transporter gene ABCC2 associated with impaired methotrexate elimination. 
Pharmacogenet.Genomics 2005;15:277-85. 




 56.  Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR et al. Genetic 
predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate 
glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite 
(SN-38) in human liver microsomes. J.Clin.Invest 1998;101:847-54. 
 57.  Jamroziak K, Balcerczak E, Smolewski P, Robey RW, Cebula B, Panczyk M et al. 
MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein 
activity in B-cell chronic lymphocytic leukemia. Pharmacol.Rep. 2006;58:720-8. 
 58.  Jeffrey WH, Paul JH. Effect of 5-Fluoro-2'-Deoxyuridine on [H]Thymidine 
Incorporation by Bacterioplankton in the Waters of Southwest Florida. Applied and 
Environmental Microbiology 1988;54:331-6. 
 59.  Kanai Y, Endou H. Heterodimeric amino acid transporters: molecular biology and 
pathological and pharmacological relevance. Curr.Drug Metab 2001;2:339-54. 
 60.  Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB et al. Multidrug resistance-1 
gene polymorphisms associated with treatment outcomes in de novo acute myeloid 
leukemia. International Journal of Cancer 2006;118:2195-201. 
 61.  Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. 
Transport mechanism and substrate specificity of human organic anion transporter 2 
(hOat2 [SLC22A7]). Journal of Pharmacy and Pharmacology 2005;57:573-8. 
 62.  Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Archiv.European 
Journal of Physiology 2004;447:666-76. 
 63.  Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, 
function, physiological roles, and biopharmaceutical implications. Pharmaceutical 
Research 2007;24:1227-51. 
 64.  Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP 
transporters. Naunyn Schmiedebergs Arch.Pharmacol. 2006;372:432-43. 
 65.  Kruse JP, Gu W. Modes of p53 regulation. Cell 2009;137:609-22. 
 66.  Kuhne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G, Brockmoller J. Influx and 
efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in 
MDR1 overexpressing tumor cell lines. Biochemical Pharmacology 2009;78:45-53. 
 67.  Kullak-Ublick GA, Glasa J, Boker C, Oswald M, Grutzner U, Hagenbuch B et al. 
Chlorambucil-taurocholate is transported by bile acid carriers expressed in human 
hepatocellular carcinomas. Gastroenterology 1997;113:1295-305. 
 68.  Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal 
physiology and liver disease. Gastroenterology 2004;126:322-42. 
 69.  Lebeau B, Chouaid C, Baud M, Masanes MJ, Febvre M. Oral second- and third-line 
lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer. 
Lung Cancer 2009. 




 70.  Lee SG, Choi JR, Kim JS, Park TS, Lee KA, Song J. Therapy-related acute 
lymphoblastic leukemia with t(9;22)(q34;q11.2):a case study and review of the 
literature. Cancer Genetics and Cytogenetics 2009;191:51-4. 
 71.  Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance 
protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001;167:3-23. 
 72.  Leslie EM, Ito K, Upadhyaya P, Hecht SS, Deeley RG, Cole SP. Transport of the beta 
-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). 
Requirement for glutathione or a non-sulfur-containing analog. Journal of Biological 
Chemistry 2001;276:27846-54. 
 73.  Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, Cole SP. Modulation of multidrug 
resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with 
dietary flavonoids. Molecular Pharmacology 2001;59:1171-80. 
 74.  Li L, Meier PJ, Ballatori N. Oatp2 mediates bidirectional organic solute transport: a 
role for intracellular glutathione. Molecular Pharmacology 2000;58:335-40. 
 75.  Loadman PM, Calabrese CR. Separation methods for anthraquinone related anti-
cancer drugs. J.Chromatogr.B Biomed.Sci.Appl. 2001;764:193-206. 
 76.  Lubbert M, Muller-Tidow C, Hofmann WK, Koeffler HP. Advances in the treatment 
of acute myeloid leukemia: from chromosomal aberrations to biologically targeted 
therapy. J.Cell Biochem. 2008;104:2059-70. 
 77.  Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L et al. 
Quantitative analysis of nucleoside transporter and metabolism gene expression in 
chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -
insensitive populations. Blood 2005;105:767-74. 
 78.  Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R et al. Levels of 
multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer 
correlate with in vitro resistance to taxol and doxorubicin. Clinical Cancer Research 
1998;4:389-98. 
 79.  Meier PJ, Stieger B. Bile salt transporters. Annu.Rev.Physiol 2002;64:635-61. 
 80.  Mertens D, Philippen A, Ruppel M, Allegra D, Bhattacharya N, Tschuch C et al. 
Chronic lymphocytic leukemia and 13q14: miRs and more. Leukemia and Lymphoma 
2009;50:502-5. 
 81.  Mertl M, Daniel H, Kottra G. Substrate-induced changes in the density of peptide 
transporter PEPT1 expressed in Xenopus oocytes. Am.J.Physiol Cell Physiol 
2008;295:C1332-C1343. 
 82.  Molina-Arcas M, Bellosillo B, Casado FJ, Montserrat E, Gil J, Colomer D et al. 
Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 
2003;101:2328-34. 




 83.  Molina-Arcas M, Marce S, Villamor N, Huber-Ruano I, Casado FJ, Bellosillo B et al. 
Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex 
vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 
2005;19:64-8. 
 84.  Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer 
resistance protein (BCRP/ABCG2) in chemotherapy. Adv.Drug Deliv.Rev. 
2009;61:26-33. 
 85.  Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter 
OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-
ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide 
polymorphisms. Drug Metab Dispos. 2005;33:434-9. 
 86.  Ohashi R, Tamai I, Inano A, Katsura M, Sai Y, Nezu J et al. Studies on functional 
sites of organic cation/carnitine transporter OCTN2 (SLC22A5) using a Ser467Cys 
mutant protein. Journal of Pharmacology and Experimental Therapeutics 
2002;302:1286-94. 
 87.  Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T et al. Characterization of 
the organic cation transporter SLC22A16: a doxorubicin importer. Biochemical and 
Biophysical Research Communications 2005;333:754-62. 
 88.  Pajor AM. Molecular properties of the SLC13 family of dicarboxylate and sulfate 
transporters. Pflugers Archiv.European Journal of Physiology 2006;451:597-605. 
 89.  Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 
2009;23:449-56. 
 90.  Pan G, Elmquist WF. Mitoxantrone permeability in MDCKII cells is influenced by 
active influx transport. Mol.Pharm. 2007;4:475-83. 
 91.  Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J. 
Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 2004;18:385-93. 
 92.  Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk 
of malignancy. Journal of the American Academy of Dermatology 2009;60:1001-17. 
 93.  Pierre K, Pellerin L. Monocarboxylate transporters in the central nervous system: 
distribution, regulation and function. Journal of Neurochemistry 2005;94:1-14. 
 94.  Ponisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G et al. Treatment 
of bendamustine and prednisone in patients with newly diagnosed multiple myeloma 
results in superior complete response rate, prolonged time to treatment failure and 
improved quality of life compared to treatment with melphalan and prednisone--a 
randomized phase III study of the East German Study Group of Hematology and 
Oncology (OSHO). Journal of Cancer Research and Clinical Oncology 
2006;132:205-12. 




 95.  Rabow AA, Shoemaker RH, Sausville EA, Covell DG. Mining the National Cancer 
Institute's tumor-screening database: identification of compounds with similar cellular 
activities. Journal of Medicinal Chemistry 2002;45:818-40. 
 96.  Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. 
Nat.Rev.Mol.Cell Biol. 2009;10:218-27. 
 97.  Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. 
Curr.Osteoporos.Rep. 2003;1:45-52. 
 98.  Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM et al. Recent 
molecular advances in studies of the concentrative Na+-dependent nucleoside 
transporter (CNT) family: identification and characterization of novel human and 
mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine 
nucleosides (system cib). Molecular Membrane Biology 2001;18:65-72. 
 99.  Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM et al. Molecular 
identification and characterization of novel human and mouse concentrative Na+-
nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine 
and pyrimidine nucleosides (system cib). Journal of Biological Chemistry 
2001;276:2914-27. 
 100.  Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: 
biopharmaceutical, physiological, and pathological roles. Pharmaceutical Research 
2007;24:450-70. 
 101.  Robak T, Korycka A, Lech-Maranda E, Robak P. Current status of older and new 
purine nucleoside analogues in the treatment of lymphoproliferative diseases. 
Molecules. 2009;14:1183-226. 
 102.  Rowinsky EK, Donehower RC. Paclitaxel (taxol). New England Journal of Medicine 
1995;332:1004-14. 
 103.  Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al. Irinotecan 
plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study 
Group. New England Journal of Medicine 2000;343:905-14. 
 104.  Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. 
Nature 1979;277:665-7. 
 105.  Shang T, Uihlein AV, Van Asten J, Kalyanaraman B, Hillard CJ. 1-Methyl-4-
phenylpyridinium accumulates in cerebellar granule neurons via organic cation 
transporter 3. Journal of Neurochemistry 2003;85:358-67. 
 106.  Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA et al. Quantitation of 
doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR 
human cancer cells. Journal of Pharmacology and Experimental Therapeutics 
2008;324:95-102. 
 107.  Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H et al. Expression 
of human organic cation transporter 3 in kidney carcinoma cell lines increases 




chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Research 
2009;69:1494-501. 
 108.  Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of 
OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer 
Biol.Ther. 2005;4:815-8. 
 109.  Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Nacheva EP et 
al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent 
mechanism. Blood 2008;112:3827-34. 
 110.  Suzuki Y, Niitsu N, Hayama M, Katayama T, Ishii R, Osaka M et al. 
Lymphoproliferative disorders after immunosuppressive therapy for aplastic anemia: a 
case report and literature review. Acta Haematologica 2009;121:21-6. 
 111.  Takeba Y, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y et al. 
Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular 
carcinoma apoptosis. J.Pharmacol.Sci. 2007;104:232-42. 
 112.  Takeba Y, Sekine S, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y et al. Irinotecan-
induced apoptosis is inhibited by increased P-glycoprotein expression and decreased 
p53 in human hepatocellular carcinoma cells. Biological and Pharmaceutical Bulletin 
2007;30:1400-6. 
 113.  Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and 
out of cells: implications for drug resistance. Blood 2004;104:3739-45. 
 114.  Thomas X, Archimbaud E. Mitoxantrone in the treatment of acute myelogenous 
leukemia: a review. Hematology and Cell Therapy 1997;39:63-74. 
 115.  Tsuji A. Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 
2002;17:253-74. 
 116.  Tucci M, Quatraro C, Dammacco F, Silvestris F. Role of active drug transporters in 
refractory multiple myeloma. Curr.Top.Med.Chem. 2009;9:218-24. 
 117.  Turk D, Szakacs G. Relevance of multidrug resistance in the age of targeted therapy. 
Curr.Opin.Drug Discov.Devel. 2009;12:246-52. 
 118.  Uwai Y, Taniguchi R, Motohashi H, Saito H, Okuda M, Inui K. Methotrexate-
loxoprofen interaction: involvement of human organic anion transporters hOAT1 and 
hOAT3. Drug Metab Pharmacokinet. 2004;19:369-74. 
 119.  Vigneswaran N, Beckers S, Waigel S, Mensah J, Wu J, Mo J et al. Increased 
EMMPRIN (CD 147) expression during oral carcinogenesis. Experimental and 
Molecular Pathology 2006;80:147-59. 
 120.  Vousden KH, Lane DP. p53 in health and disease. Nat.Rev.Mol.Cell Biol. 2007;8:275-
83. 




 121.  Wang H, Fei YJ, Kekuda R, Yang-Feng TL, Devoe LD, Leibach FH et al. Structure, 
function, and genomic organization of human Na(+)-dependent high-affinity 
dicarboxylate transporter. Am.J.Physiol Cell Physiol 2000;278:C1019-C1030. 
 122.  Yamaguchi H, Chen J, Bhalla K, Wang HG. Regulation of Bax activation and 
apoptotic response to microtubule-damaging agents by p53 transcription-dependent 
and -independent pathways. Journal of Biological Chemistry 2004;279:39431-7. 
 123.  Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T et al. Rapid 
screening of antineoplastic candidates for the human organic anion transporter 
OATP1B3 substrates using fluorescent probes. Cancer Letters 2008;260:163-9. 
 124.  Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T et al. Human L-
type amino acid transporter 1 (LAT1): characterization of function and expression in 
tumor cell lines. Biochimica et Biophysica Acta 2001;1514:291-302. 
 125.  Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD. Transport of 
antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, 
nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins 
produced in Xenopus oocytes. Molecular Membrane Biology 2001;18:161-7. 
 126.  Yao YY, Zhu Q, Zou LF, Dou HJ, Chen YM, Tang Y et al. [Clinical study on 
fludarabin combined with cytarabine regimen in the treatment of patients with 
refractory and relapsed acute myeloid leukemia.]. Zhongguo Shi Yan.Xue.Ye.Xue.Za 
Zhi. 2009;17:774-6. 
 127.  Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, Heuberger M et al. Treatment 
resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leukemia 
and Lymphoma 2009;50:510-3. 

























I hereby declare that the work described in this thesis was performed by me unless 
otherwise specified. This thesis was written by me and submitted to the Georg-August-
Universität, Göttingen, Germany to obtain the Doctoral degree from the Faculty of 
Mathematics and Natural Sciences. 
 
 









































I express my sincere gratitude to my supervisor PD Dr. Yohannes Hagos, for his support, 
encouragement and unfailing patience throughout my thesis. It is not often that one finds 
an advisor who always takes the time to listen to problems and help through the 
roadblocks that unavoidably crop up in the course of research. His guidance was essential 
for the completion of this work. 
 
I gratefully acknowledge the contribution of Prof. Dr. Gerhard Burckhardt who has helped 
shape the direction of my research through numerous spirited discussions. I thank Prof. 
Dr. Thomas Pieler and Prof. Dr. Uwe Gross for agreeing to review my work.  
 
I also acknowledge the cooperation extended to me by all members of the lab. I specifically 
thank Prof. Dr. B.C. Burckhardt and PD Dr. Wolfgang Krick for the discussions and help 
in problem solving. I thank Mr. Soeren Petzke and Ms. Gesche Dallmeyer for their help in 
the lab.  
 
I would also like to thank Prof. Dr. Gerald Wulf for his collaboration in this project. 
 
I thank all my friends here, especially Nina Schnedler, for a wonderful time and support 
these three years. 
 
My family receives my deepest gratitude and affection for their good cheer and 
encouragement that enabled me to get through periods of academic doubt and anxiety. 
 








Name:   Shivangi Gupta   
 
Date of Birth:   14.07.1983   
 
Nationality:   Indian 
 
1986-2001:  Schooling (Nursery-Class XII), RSJMS and Modern School,  
  Barakhamba Road, New Delhi, India 
 
2001- 2004:  B.Sc(Hons) Biotechnology, Ch. Charan Singh University, Meerut, 
  India 
 
2004- 2006:  M.Sc. Biochemistry and Molecular Biology, University of Bremen, 
  Germany  
    Master Thesis: Identification of new splice variants and differential 
  expression of HRP-2. (Centre for Biomolecular Interactions Bremen, 
  Universität Bremen) 
 
2006- 2009:  Dr.rer.nat (Ph.D Biology), Dept. of Vegetative Physiology, University 
  of Göttingen, Germany 
    Ph.D thesis: Expression of SLC transporters in Chronic Lymphocytic 




1.   Shnitsar Volodymyr, Eckardt Ronny, Gupta Shivangi, Grottker Julia, Müller 
 Gerhard A, Koepsell Hermann, Burckhardt Gerhard, Hagos Yohannes 
   Expression of human organic cation transporter 3 in kidney carcinoma cell 
 lines increases chemosensitivity to melphalan, irinotecan, and vincristine. 
 Cancer Research 2009 
 
2.    Thakar Ketan, Niedenthal Rainer, Okaz Elwy, Franken Sebastian, Jakobs 
 Astrid, Gupta Shivangi, Kelm Sørge, Dietz Frank 
   SUMOylation of the hepatoma-derived growth factor negatively influences its 












Mar 25–28, 2007 Deutsche Physiologische Gesellschaft Congress 2007, Hannover,  
  Germany 
 
Aug 11–17, 2007  BioMedical Transporters 2007: Membrane Transporters in Disease and 
  Drug Development, Bern, Switzerland 
 
Sept 12–15, 2007 Aggressive Lymphoma Workshop 2007, Göttingen, Germany 
 
Mar 2–5, 2008  Deutsche Physiologische Gesellschaft Congress 2008, Cologne,  
  Germany 
    Poster: Interaction of cytostatics with organic cation transporters 1& 2 
 
Jun 12–14, 2008  CESAR Congress, Göttingen, Germany 
 
Nov 12–22, 2008  Goettinger Transport Tag 2008, Göttingen, Germany 
    Talk: Interaction of cytostatics with organic cation transporters 1 and 2 
 
Mar 22–25, 2009  Deutsche Physiologische Gesellschaft Congress 2009, Giessen,  
  Germany 
    Poster: Organic cation transporter mediated cytotoxicity of irinotecan 
  and paclitaxel 
